City University of New York (CUNY)

CUNY Academic Works
Dissertations, Theses, and Capstone Projects

CUNY Graduate Center

9-2016

Tuning into Toxins and Channels: The Characterizations of Tv1
and a Human Cardiac Sodium Channel Voltage-Sensor Domain
Mohammed H. Bhuiyan
The Graduate Center, City University of New York

How does access to this work benefit you? Let us know!
More information about this work at: https://academicworks.cuny.edu/gc_etds/1578
Discover additional works at: https://academicworks.cuny.edu
This work is made publicly available by the City University of New York (CUNY).
Contact: AcademicWorks@cuny.edu

Tuning into Toxins and Channels:
The Characterizations of Tv1 and a Human Cardiac Sodium Channel
Voltage-Sensor Domain
By
Mohammed H. Bhuiyan

A dissertation submitted to the Graduate Faculty in Biochemistry in partial fulfillment of
the requirements of the degree of Doctor of Philosophy
The City University of New York
2016

©2016
Mohammed H. Bhuiyan
All Rights Reserved
II

This manuscript has been read and accepted for the Graduate Faculty in Biochemistry
in satisfaction of the dissertation requirement for the degree of Doctor of Philosophy.

____________
Date

________________________________
Dr. Sébastien F. Poget
(Chair of Examining Committee)

____________
Date

________________________________
Dr. Edward J. Kennelly
(Executive Officer)

Dr. Fred R. Naider
(College of Staten Island)
Dr. Mandë Holford
(Hunter College)
Dr. Ming Tang
(College of Staten Island)
Dr. Thomas V. McDonald
(Albert Einstein College of Medicine)
Supervisory Committee

The City University of New York
III

Abstract
Tuning into Toxins and Channels:
The Characterizations of Tv1 and a Human Cardiac Sodium Channel Voltage-Sensor
Domain
by
Mohammed H. Bhuiyan
Advisor: Dr. Sébastien F. Poget
In nature, peptide toxins are an abundant resource, produced both by marine and
terrestrial organisms. A major target of these peptide toxins is the group of the highly
important voltage-gated ion channels. Due to their high specificity and affinity, peptide
toxins have been used for over a decade in discovery and characterization of voltagegated ion channels. Although peptide toxins have been extensively characterized
structurally, the structural characterization of eukaryotic voltage-gated sodium channels
has seen much less progress, due to their large size and high hydrophobicity. Voltagegated sodium channels play crucial roles in many physiological processes, and when
these processes are disrupted, due to malfunctioning ion channels, they lead to
diseased states known as channelopathies. It is believed that some channelopathies
can be corrected through fine tuning of the gating properties of the diseased channels
through the use of drugs or peptide toxins. If the structural interactions of these peptide
toxins with their cognate voltage-gated sodium channels can be unraveled, we may be
able to use them as drugs directly or as lead compounds for the thoughtful design of
small molecules that exploit these interactions. Here, I have taken the following steps
towards an increased structural understanding of ion channel-toxin interactions:
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Firstly, we have shed light on the first high-resolution structure of a novel class of
peptide toxins known as teretoxins with the determination of the structure of Tv1. Tv1
was isolated from the terebrid marine snail Terebra variegata in nanogram quantities
and its sequence determined by direct mass spectrometry sequencing. The peptide
was chemically synthesized and refolded, and then subjected to solution-state NMR
experiments. We were able to solve the structure of Tv1 to a resolution 0.74 Å using 2Dhomonuclear/heteronuclear NMR techniques. Although Tv1’s target remains elusive,
structural features suggest that its natural target is an ion channel.
Voltage-sensor domains of voltage-gated ion channels are responsible for
sensing changes in the membrane potential of excitable cells and translating this
information into the various states of the pore (open, closed, inactivated), but the
mechanism by which these states are transferred from the voltage-sensor domain to the
channel remains unknown. Here we have expressed a voltage-sensor domain of the
human cardiac voltage-gated sodium channel. We have demonstrated the ability to
isotopically label the voltage-sensor domain in a bacterial expression system.
labeled voltage-sensor domain was subjected to

15N-TROSY

15N-

experiments to

demonstrate the feasibility of structural studies. The Voltage-Sensor Domain under
study produced little to no signal in n-DPC micelles, but marked improvement was
obtained in a bicelle system. In spite of such improvement, system conformational
heterogeneity seems to be apparent. We were also able to pull down a toxin from the
venom of the tarantula Grammastola rosea using immobilized voltage-sensor domain,
with the potential establishment of a method for the discovery of novel site 3 toxins by
pull down with NaV1.5.

V

Paddle motifs are the target of many gating-modifier toxins and have been shown
to bind toxins independent of their background (placement into non-native channels)
and in isolation. Here we present the synthesis (both chemical and biological) and
characterization of a mammalian 37 residue NaV paddle motif. We subjected an
isotopically labeled paddle motif of DIV of the human cardiac voltage-gated sodium
channel (NaV1.5) to various 2D and 3D NMR experiments and assigned 86% of the
backbone residues. We also recorded NMR spectra of the paddle motif in the presence
of ApA, a known site-3 gating modifier toxin, which yielded complete loss of NMR signal,
indicating that an interaction is occurring. Through the establishment of our backbone
assignments, interactions of known site 3 gating-modifier toxins and NaV1.5 DIV S3-S4
paddle motif can be characterized, yielding mechanistic insights and knowledge that
could be used in drug design.
Peptide toxins and voltage-gated ion channels have been used to unravel the
secrets of each other for years, and our work continues in that direction. With Tv1 we
have shown the ability to structurally characterize a peptide toxin using limited
resources, which will open the door to structurally characterizing toxins thought to be
restricted due to sample size limitations. With the NaV1.5 VSD and paddle motif of DIV
we have presented a strategy to express and structurally characterize transmembrane
fragments of a eukaryotic voltage-gated sodium channel in the absence and presence
of gating-modifier toxins by NMR spectroscopy. Taken together, the experiments we
conducted have increased the atomic level knowledge of toxin and eukaryotic voltagegated ion channel biology.
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Chapter 1

Introduction
1.1 Ion Channels
The plasma membrane defines a cellular unit by creating an impermeable barrier
to hydrophilic molecules between the exterior and the interior of a cell. Ion channels are
therefore like molecular gate keepers of the cell, allowing or impeding signals into and
out of the cell. Ion channels are a class of integral membrane proteins and are of
extreme importance to a diverse array of physiological process such as, but not limited
to, hormone release (1), propagation of the heart beat (2) and nerve impulses (3). Ion
channels perform these tasks by maintaining and altering membrane potentials by
allowing the selective passage of ions across the membranes in which they are
embedded. Ion channels are divided into subclasses based on their mechanism of
gating; voltage-gated (4), ligand-gated (5), mechano-gated (6), and temperature gated
(7).

1.2 Voltage-gated Ion Channels
Voltage-gated ion channels (VGICs), are important in detecting differences in
membrane potential and therefore can propagate muscle contractions and action
potentials in various tissues such as cardiac muscle, smooth muscle, and neurons;
known as excitable tissues and cells. VGICs consist of two main functional domains - a
central pore that allows for passage of ions through the membrane, and a voltage1

ARTICLE IN PRESS
W.A. Catterall et al. / Toxicon 49 (2007) 124–141

nerve,
and closed
endocrine cells
hannels are sensor
the molecular
targets
a widetherange
domain (VSD)
whichfor
regulates
different states
of themuscle,
channel (open,
labeling, purification and functional
potent biological toxins, including the gating
and
inactivated)
based
on
the
membrane
potential.
Channelsthat
are sodium
made of four
showed
channels from
odifier toxins that alter the kinetics and voltage
contain- each
voltage-sensing
and
ependence symmetrically
of their activation
and inactivation.
arranged subunits
(known as domainsbrain
I-IV (DI-DIV))
subunit
elements in a single protein complex o
his introductory chapter introduces the voltageconsisting
of
6
transmembrane
domains
(TMs).
TMs
(typicallyofknown
as S1-S4)
a1-4subunit
220–260
kDa and one or
ated ion channels, gives an overview of the
b subunits
approximately
33–36 k
ommon features
of oftheir
structure
from each
the subunits
form and
the 4 function,
flanking voltage-sensor
domainsof
(VSDs),
and TMs
1984, 2000a). The a subunits of sodium
resents the sodium channel as a primary example
and 6 (S5-S6)
from
all the subunits
form the tetrameric
pore domain.
voltage-gated
composed
of Infour
homologous doma
neurotoxin5 action
on ion
channels,
and describes
contain six hydrophobic transmemb
e voltage-sensor
trapping model for gating modiK+ channels (Kv), all four domains are identical protein monomers, whereas in
(Fig. 1). A membrane-reentrant loop
er toxin action, which may be a common mechan+
2+
eukaryotic
voltage-gated
Naion
and
Ca channels (Navfifth
and and
Cav respectively),
the S6)
four transmemb
sixth (S5 and
m of polypeptide
toxin
action on
channels.
forms the narrow extracellular end of
domains are encoded by one protein (Figure 1.1; (8)). The loops between S5 and S6 of
the S6 segments form the intracellular
1. Voltage-gated sodium channels
repeats DI-DIV form the ion selectivity filter conferring
ion specificity
to theis channel
red).
The pore
formed in the
pseudosymmetric array of the four d
The founding
member
ofthe
theintracellular
ion channel
protein,
whereas
partssuperof S6 from each domain form an apex or
single a subunit containing four dom
mily in terms of its discovery as a protein is the
known
as the These
gate, which
can impede
ion flow.
The internal
receive
voltage
signalsgate
andis activate its
oltage-gatedaperture
sodium
channel.
channels
are or allow
The channel responds to voltage by v
sponsible for
the rapid influx of sodium ions that
controlled by the S4-S5 loop, which transfers movements of the VSD due to potential
segments (Fig. 1A, green), which con
nderlies the rising phase of the action potential in
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changes in the membrane to the internal gate, allowing for the opening of the channel
aperture.

1.3 Voltage-gated Sodium Channels
NaVs were first discovered in 1952 by Hodgkin and Huxley when studying the
giant squid axon (9). NaVs come in two flavors, bacterial and eukaryotic. Bacterial NaVs
are more akin to KVs in that they are formed by four identical monomers, whereas the
eukaryotic NaVs are formed by one protein in a pseudotetrameric fashion. There have
been studies on only 9 isoforms of eukaryotic NaVs from subfamily 1 (NaV1.1-1.9)
described to date (10) and on an NaV2 subfamily who's function is not well

Figure 1.2: NaV isoform tissue specific expression profile. NaV1.1-1.9 are expressed in various
tissues from the CNS, PNS, smooth muscle, skeletal muscle, cardiac, and even cancer cells.
Channelopathies are listed on the right. Image from (12).

3

NOMENCLATURE AND RELATIONSHIPS OF VOLTAG

Figure 1.3: NaV amino acid sequence homology. NaV1.1-1.3, and 1.7 are most closely related of all
the NaVs. Although all NaVs as a whole share greater than 50% sequence homology. Image from (13).

characterized showing less than 50% homology to subfamily 1 (11). All NaV isoforms are
expressed in a tissue specific manner (Figure 1.2; (12)). The nine Nav isoforms can be
separated into two groups, the tetrodotoxin (TTX) resistant (TTX-R) and the TTX
sensitive (TTX-S) channels. NaV1.1-1.4, 1.6 and 1.7 are all TTX-S and are affected by
TTX in the nM concentration range, whereas NaV1.5, NaV1.8, and NaV1.9 are TTX-R
and affected in the mM range (13). All nine isoforms share greater than 50% amino acid
sequence homology (Figure 1.3, (13)). In nature, NaVs are found as a ~260 kDa αsubunit associated with one or more β-subunits (1-4 depending on the tissue). Although
the NaV α-subunits are enough to conduct Na+ ions across the membrane, β-subunits
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nucleotide sequences, and the nucleotide sequence alignments were subjected to analysis using the program PAUP*. Divergent portions of the
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of channel activation (15). This quick inactivation allows for the repetitive firing in
excitable cells. The function of NaVs is not limited to the initiation and propagation of
action potentials. They have also been shown to be involved in cellular functions of nonexcitable cells such as phagocytosis, cell motility, and metastasis as reviewed by Black
et al (16). Due to their diverse and important roles in mammalian physiology, it should
be no surprise that numerous mutations cause diseased states called channelopathies.
2586
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Mutations (mostly missense, but also less frequently insertion, deletion or nonsense

Figure 1.4: Action potentials of NaVs. Black traces represent the membrane potential of a (A) neuron
and (B) cardiomyocyte during an action potential with the dotted line representing the resting membrane
potential. Red traces represent the sodium current of the respective cell types during the action
potential. Circled numbers represent the different states of the NaV during the action potential;
closed
state, open state, and
inactivated state. Image from (10).
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mutations) that lead to channelopathies affect the gating properties of NaVs, leading to
hyper- or hypo-excitability or elongated sodium currents due to loss of fast inactivation.
Channelopathies include autism (17), epilepsy (18, 19), cardiac arrhythmias (20), pain
(21), and more (22).

1.4 Voltage-Sensor Domains
The VSDs of NaVs are highly conserved throughout nature amongst VGICs, with
two conserved residues in S1, four in S2, one in S3, and four in S4 even showing a
coupled conservation amongst these residues (meaning residues of these positions are
conserved in pairs) (23). The TM S4 contains a positively charged residue at every third
position, typically arginine or lysine (known as R1, R2, R3, R/K4). This grouping of
positive charge is what led early researchers to believe that S4 was the voltage-sensor
of membrane potentials in the VSD. Early on there were three leading models of how
VSDs translate differences in membrane potential to channel activity as reviewed in
(24). The first model is known as the helical screw/sliding-helix model. This model
suggests that the conserved positive charges in S4 are satisfied by negative charges
elsewhere in the protein, and upon a change in the membrane potential S4 moves 4.5Å
and rotates 60° per charge moved, allowing the conserved positive charges to make
new contacts. The second model proposes that the charge transfer of the S4 conserved
positive charges upon membrane potential change is largely rotational (~180°) and less
of a translational motion (2-4Å). This model is known as the rocking banana model
(transporter). The third model (paddle model) puts forth the idea that S3b (a semi
conservative proline in S3 creates a kink separating the TM into two helices) and S4
6

Figure 5. S
Segment th
Activation o
NaChBac

Figure 1.5: Proposed mechanism of action of the NaV voltage-sensor domain. Model of VSD
activation in NaChBac showing the transition of the voltage-sensor through the gating pore. Breaking and
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move as one unit, and complete the gating cycle as one unit, moving outward by
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X-ray crystallography), most of them are of KV (28-31) and bacterial NaV channels (32,
33, 34). All structures to date have shown the VSDs in what is thought to be an
activated state, this is because there is no membrane potential to increase the
probability that VSDs will take a non-activated state. There has been one eukaryotic
NaV structure to date from Electrophorus electricus produced by cryo-electron
microscopy (cryo-EM) to a very low resolution of 19Å (35) and a chimeric humanbacterial structure of NaV1.7/NaVAb where the top half of the VSD including its
extracellular loops of NaV1.7 DIV replaced those of NaVAb (34). There has also been a
structure of the CaV1.1 in complex with its α2δ, β, and ɣ subunits solved by cryo-EM to
a resolution of 4.2Å (36). Although cryo-EM is deemed to be the future of structural
biology (37), it has yet to prove itself in the realm of VGIC structural biology with only
one high resolution structure produced (35, 36).
One way to aid in producing structures of VGICs would be to implement solutionstate nuclear magnetic resonance spectroscopy (NMR). Using NMR over
crystallography has its benefits, such as allowing the dynamics of the system under
study to be probed, and, in contrast to crystallography, little to no modifications are
needed for increasing the rigidity and stability of the protein. One area where NMR does
fall short for proteins (especially membrane proteins), is that it is limited by the size of
the total complex. Due to the size of integral membrane proteins and their membrane
mimetic, complexes may be too large leading to slow isotropic tumbling and spectral
line broadening. Since TMs are highly helical, the nuclear environments of different
residues may also be highly similar, leading to large spectral overlap. One way to
overcome the size limitations is to study portions or subunits of proteins. In nature,
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subunits are known to fold independently of each other as opposed to needing all
subunits present to fold correctly. This has been shown in G-protein coupled receptors
(GPCRs) as well as VGICs. Fragments of the GPCR Ste2p were co-expressed in yeast,
and were found to form functional receptors (38), indicating that fragments could
potentially fold independently of each other into native folds. This has also been proved
structurally and functionally for VGICs. The MacKinnon group solved the crystal
structure of KvAP in complex with an antibody fragment (29) as well as both the X-ray
crystal and solution-state NMR structure of the isolated VSD (28) of the same protein,
showing that the VSD adopts a similar fold in the intact channel as it does in isolation
(with the largest deviation between the two structures being an RMSD of 2 Å most likely
due to distortions induced by co-crystallization with an antibody fragment), and more
closely resembles the KV1.2-KV2.1 paddle chimera structure(39) with an RMSD of 0.84
Å. Paddle motifs (a helix-turn-helix motif formed by the S3b and S4 TMs and their
connecting loop) of NaVs had been placed into KV2.1 replacing its own paddle motif and
shown to produce functional chimeric channels able to conduct K+ ions upon
depolarization, and bind NaV gating-modifier toxins (26). Additionally the isolated paddle
motif from NaV1.2 VSD IV was used in surface plasmon resonance (SPR) studies where
it was able to bind toxin (40). This justifies the idea of studying isolated paddle motifs
and VSDs of NaVs, since the VGICs and their VSDS in particular share very strong
structural homology.
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1.6 Peptide Neurotoxins
Peptide neurotoxins are a rich source of natural products (41-43). A prime
example of the vast richness of peptide neurotoxins is found in the conidae family of
marine snails; each species can produce upwards of 200 unique peptide toxins, with
600-700 species and 1,500 -1700 conotoxins described so far (43, 44). Due to their high
Journal of Medicinal Chemistry
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Figure 1.6: Neurotoxin receptor sites. (A) Neurotoxin receptor sites mapped on to a 2D mammalian
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Topology of the human Nav channel α subunit indicating binding sites. (B,C) An extracellular and side view, respectively, of the crystal structure of
neurotoxins. (B) Neurotoxin receptor sites mapped on the top-down view of the extracellular side and (C)
bacterial NavMs.12 Site 1 (red) is formed by the four P-loops and represents the binding site of pore blockers, such as TTX, STX, and μ-conotoxins.
the is
planar
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for toxins
as BTX, VTD,
and
antillatoxin, which interact with S6 in DI and DIV. α-ScTxs and Ap-B modulate Nav
channels by binding to Site 3 (cyan) on the extracellular S3−S4 loop in DIV. Site 4 (blue) consists of the extracellular loops S1−S2 and S3−S4 of
DII and constitutes the binding site of β-ScTxs, ProTx-II, and HWTX-II. Site 5 (pink), which comprises S6 of DI and S5 of DIV, has been identiﬁed
as the interaction site for ciguatoxins and brevetoxins. Site 6 (orange), via S4 of DIV, binds μO- and δ-conotoxins. Site 7 (purple)
10 is the local
anesthetic binding site in the pore of the channels and consists of amino acid residues in S6 of DI, DIII, and DIV. Site 8 (yellow) is the ICA/PF site
located in the VSD of DIV.

In summary, we have illustrated the important role of Na

NATURAL PRODUCTS AND THEIR DERIVATIVES

specificity and affinity, peptide neurotoxins provide powerful tools to study structure and
function of channels. These neurotoxins can affect permeation through the channel
pore, and/or gating properties of the voltage-sensor. On eukaryotic sodium channels,
there are six known neurotoxin receptor sites described to date, and peptide
neurotoxins are known to target four of those sites (8, 12, 45) (Figure 1.6; (12)). Site 1 is
known to be the binding site of pore blockers, such as TTX, saxitoxin (STX), and μconotoxins. Sites 2-6 were found to be allosterically coupled - suggesting the
neurotoxins bound to these sites alter the equilibrium of the various channel states,
altering conformation of the channel. Neurotoxin binding sites 3 and 4 will be of great
importance in probing structural information of isolated VSDs of NaVs. Site 3
neurotoxins bind the paddle motif (S3b-S4 linker region) of DIV, and site 4 neurotoxins
bind the extracellular loops of DII VSDs. Site 6 neurotoxins may also be beneficial to
studying VSDs as they interact with the voltage-sensor of domain IV, though it is not
known if these neurotoxins exclusively bind VSD IV. These neurotoxins come from a
variety of terrestrial and marine species.

1.6.1 Spider Toxins
Spiders represent the most diverse venomous terrestrial order with over 46,000
described species curated in the world spider catalog (46). It is believed that a single
spider venom can contain over 1000 neurotoxins, estimating over 10 million spider
toxins in nature (42). To date,12 families of spider toxins that target NaVs (NaSpTx
family 1-12) have been described based on sequence identity and intercysteine
spacings (47). These spider toxins range in size from 28 to 77 residues in length with
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disulfide bonds ranging from 3 to 7 depending on the NaSpTx family (47). Families can
be sorted into two groups depending on what NaV neurotoxin site they bind. NaSpTx
Families 2, 4, and 12 target receptor site 3, NaSpTx Families 1, 3, 5, 7, and 10 target
receptor site 4, leaving NaSpTx Family 6 ,9, and 11 with a yet to be determined receptor
site and NaSpTx Family 8 targeting receptor site 1 (47). Although NaSpTx families 1, 3,
5, 7, and 10 share the same binding site, their effects are different, with NaSpTx families
1, 3, and 7 inhibiting channel activation by locking VSD II in the resting state (48-50),
whereas NaSpTx families 5 and 10 show increased channel activation (51, 52). NaSpTx
Families 2, 4, and 12 target neurotoxin receptor site 3 (S3b-S4 linker region) slowing or
preventing NaV fast inactivation (53-55). Although distinct NaSpTx families have been
proposed, spider toxins have been shown to act promiscuously, being able to not only
interact with various domain paddle motifs of the same NaV (26) but also different NaV
isoforms, and even channel subtypes (NaV, KV, CaV).

1.6.2 Scorpion Toxins
Scorpion toxins (NaScTx) come in two major types; α-NaScTxs(56) and βNaScTxs (57), which are then further subdivided in their respective clades. NaScTxs
are typically between 60 to 80 residues in length stabilized by 4 disulfide bonds. αNaScTxs and β-NaScTxs used to be classified by old world (α-NaScTxs) vs new world
(β-NaScTxs), but since the line between them is being blurred (58), they are nowadays
characterized by their neurotoxin binding site instead. α-NaScTxs bind to neurotoxin
receptor site 3 and slow or inhibit NaV fast inactivation (59, 60). They are further
subdivided into 3 classes (61): 1) classical α-NaScTxs, which target mammalian NaVs,
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2) anti-insect α-NaScTxs, which, as the name implies, target only insect NaVs, and 3) αlike α-NaScTxs, which are active on both mammalian and insect NaVs. β-NaScTxs
target neurotoxin receptor site 4 and tend to push channel activation towards more
depolarized potentials by a voltage-sensor trapping mechanism (62, 63). They are
subdivided into 4 classes (61): 1) anti-mammalian β-NaScTxs, which target mammalian
NaVs, 2) anti-mammalian/insect β-NaScTxs, which act on both mammalian and insect
NaVs, 3) anti-insect excitatory β-NaScTxs, and 4) anti-insect depressant β-NaScTxs. All
NaScTxs share a similar three dimensional βαββ fold held together by their 4 disulfide
bonds. Since NaScTxs bind to there cognate receptors in a state dependent manner,
they may hold the key to truly unraveling mechanism of action at an atomic level.

1.6.3 Sea Anemone Toxins
Sea anemone use neurotoxins for both predatory and defense mechanisms.
There have been over 50 sea anemone toxins described in the literature that target
NaVs and they mainly fall into 1 of 3 types (with a few exceptions that don't fall into any
of these 3 types) based on their sequence homology (64). Type 1 & 2 sea anemone
toxins are considered the long toxins, and are 46 to 51 residues in length with a
conserved disulfide bridge motif of Cys1-Cys5, Cys2-Cys4, Cys3-Cys6. Type 3 are the
short sea anemone toxins that are 27 to 32 residues in length with either 3 or 4 disulfide
bonds. Sea anemone toxins target neurotoxin receptor site 3, slowing or preventing fast
inactivation in NaVs as seen with anthopleurin A (ApA), anthopleurin B (ApB), and ATXII, all of which inhibit fast inactivation of NaV1.5 (65). These toxins have been shown to
bind the channel in a voltage-dependent manner (66), similarly to NaScTx.
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1.6.4 Marine Snail Toxins
The super family Conoidea represents three families of predatory marine snails,
the well studied Conidae (cone snails), and the lesser studied Terebridae (terebrids) and
Turridae (turrids). As stated earlier, each species of cone snails is thought to produce
upwards of 200 conotoxins. Considering that 1700 species have been described so far,
this creates an immensely huge natural resource library (43, 44). The well studied cone
snails have a diverse array of conotoxins with 9 pharmacological families described to
date (α, χ, δ, ε, ɣ, ɩ, κ, μ, ω, ρ, σ, conantokin), and each of these families can be further
subdivided based on their unique cysteine framework (44). Conotoxins range from 6 to
84 residues in length. Out of the 9 pharmacological families described, 3 are active
against NaVs. The μ-conotoxins are known NaV pore blockers, interacting with site 1
(67). Although the site of interaction is still not known, ɩ-conotoxins activate NaVs without
affecting fast inactivation (68, 69). Lastly δ-conotoxins interact with the voltage sensor
of domain IV, neurotoxin receptor site 6 (70, 71). δ-conotoxins are known to prolong
channel opening by slowing channel inactivation. Terebrids and Turrids, although less
studied, hold similar promise of a diverse library of biologically active NaV neurotoxins
(43) that may finally be unraveled thanks to the advent of next generation sequencing
(72).

1.6.5 A Promise of Peptide Neurotoxins
One way in which toxins can aid in structural studies is that they are known to
“lock” channels in certain conformations, be it activated, closed, or inactivated. Using
toxins known to lock channels in each specific conformation and using techniques such
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as X-ray crystallography, NMR, and even cryo-EM (if sufficiently high resolution can be
obtained), one can theoretically map a mechanism of action for the VSDs and channels.
Since peptide neurotoxins are highly specific and have great affinity for their cognate
VGIC, there is high potential for their use as a drug or a model for drug development,
fine tuning channel activity and thereby alleviating symptoms in channelopathies (73). In
2004, the Food and Drug Administration (FDA) approved ziconotide (Prialt) as a drug to
alleviate intense and chronic pain typically found in HIV and cancer patients (74).
Ziconotide is a peptide neurotoxin derived from the cone snail, Conus magus, which
alters CaVs of neuronal cells in the pain pathway (74, 75). If the toxin-VSD interaction
can be elucidated, molecules imitating the pharmacology of these peptides can be
developed, allowing for easier methods of administration, specificity, and longevity.
These interactions can be brought to light by various NMR methods (76) as well as
cross-linking and mutational studies.

1.7 Probing Biology Through NMR Spectroscopy
NMR has proven to be a powerful tool in structurally and dynamically studying proteins
since it was first used to determine the structure of proteinase inhibitor IIA from bull
seminal plasma in 1985 (77). The simplest set of NMR experiments one can run for 3D
structure determination of a protein consists of the 2-dimensional (2D) homonuclear
1H-1H

Correlation Spectroscopy (COSY), Total Correlation Spectroscopy (TOCSY), and

Nuclear Overhauser Spectroscopy (NOESY) experiments. The 2D 1H-1H COSY and
TOCSY experiments allow for the identification and establishment of amino acid spin
systems, where magnetization is transferred through bonds via j-coupling. The 2D 1H-1H
15

NOESY experiments allow for the establishment of distance restraints as magnetization
is transferred through space via dipolar couplings. Using the two types of experiments in
conjunction allows sequential assignments to be made, and has been termed a COSY/
TOCSY-NOESY walk. These 2D 1H-1H homonuclear techniques are routine for structure
determination of soluble proteins less than 55 residues in length - typical of peptide
toxins (78, 79). For proteins larger than 55 residues the spectral overlap in 2D
homonuclear 1H-NMR becomes too great to overcome, and isotopic labeling with
and

13C

15N

is needed. Isotopic labeling of proteins allows 2D and 3-dimensional (3D)

heteronuclear experiments that reduce the spectral overlap. 3D triple resonance NMR
experiments such as HNCOCA(CB) and HNCA(CB) have made sequential assignments
routine for larger proteins. However, an important drawback of working with large
proteins or systems (such as membrane proteins solubilized in membrane mimetics) is
the slow isotropic tumbling of the system leading to increased line broadening with
increased molecular weight. One way to circumvent this issue is through the use of 2D
and 3D transverse relaxation-optimized spectroscopy (TROSY) based experiments,
where the spectral sensitivity and resolution is improved as discussed by Fernández
and Wider (80) and demonstrated for various membrane proteins in both micelles (28,
81) and even larger bicelles (82, 83). NMR is not only useful for deriving structural
information, but is also a powerful method for looking at binding interactions and
dynamic states ranging on the time scales of picoseconds to seconds, and even longer.
Experiments such as cross saturation can be used to determine direct binding
interfaces of biomolecules, as was done to determine the residues involved in binding of
the peptide toxin VSTx1 with the VSD of KVAP in n-decyl-ß-D-maltopyranoside (DM)
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micelles (84). Binding can also be probed using changes in peak position in

15N-

heteronuclear single quantum coherence spectroscopy (HSQC), which will not only
provide information on residues involved in binding but also residues involved in
conformational changes. NMR spectroscopy can also give information about protein
backbone flexibility (spin relaxation experiments), orientational information based on
residual dipolar couplings (RDCs), and protein folding and unfolding (ZZ exchange
experiments) - all reviewed in (85, 86). The ability of NMR to not only determine protein
structure, but also probe protein dynamics makes NMR an invaluable tool for the life
sciences.

1.8 Scope of Work
Our group is interested in the structural characterization of peptide neurotoxins,
in establishing a method for the discovery of novel gating-modifier toxins, and in
elucidating VGIC structure and the interactions of gating-modifier toxins with their
cognate receptors. Specifically we are interested in the structure of peptide neurotoxins
and the VSDs of NaV channels. Here we bacterially expressed a human VSD (NaV1.5
VSD IV) in quantifiable amounts, with the ability to isotopically label the protein. By
immobilizing VSDs on a resin we were able to probe venom extract to pull down novel
toxins. We have also subjected synthesized and folded peptide neurotoxins and NaV
paddle motifs to various solution-state 2D homonuclear NMR techniques such as
TOCSY and NOESY, 2D and 3D heteronuclear HSQC (both 1H-15N and 1H-13C), HNCO,
HNCA, and HNCACB in structural characterization. Using the

15N

TROSY we were able
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to probe the feasibility of making sequential backbone assignments of the isolated
human cardiac Nav1.5 VSD IV.
The determination of assignments using NMR spectroscopy on isolated VSDs or
paddle motifs and their neurotoxin complexes can reveal the interacting residues of
toxins and their cognate receptors at atomic resolution(76). Elucidation of these key
interactions of the (VSD/paddle motif)-toxin complexes and the conformational changes
induced by the toxins (correlating with altered physiological responses or voltagedependent states) may facilitate the development of novel compounds that target and
affect voltage activation of VGICs. NMR is a great tool for determining protein-protein
(or ligand-protein) interactions, especially within the realm of membrane proteins (76,
84). NMR allows for the visualization of protein dynamics, as relaxation properties of the
nuclei within the protein will change based on the dynamic environment of the nuclei.
Whereas membrane proteins are highly flexible and hydrophobic, which greatly
decreases their ability to be crystallized, solution-state NMR allows for the structural
study of membrane proteins by overcoming these difficulties since experiments can be
conducted in a more native state using phospholipid bicelles. With the structural
information obtained by way of solution state protein NMR, the development of novel
therapeutic compounds can ensue that would capitalize on key interactions to increase
specificity and lessen side effects caused by nonspecific interactions.

18

Chapter 2
NMR Structure Of Tv1, A Novel Bioactive Peptide
Toxin from Terebrid Marine Snails
Mohammed Bhuiyan, Prachi Anand, Alexandre Grigoryan, Jianqin Zhuang, Mandë
Holford, Sébastien F. Poget
Adapted from the 2012 publication: Anand, Prachi, et al. "Sample limited characterization of a novel disulfide-rich venom peptide
toxin from terebrid marine snail Terebra variegata." PloS one 9.4 (2014): e94122.

2.1 Abstract
Peptide toxins display great specificity in both targeting and function, and are a
viable resource for enriching the available arsenal of pharmaceutical compounds. For
example Ziconotide (Prialt), a peptide toxin derived from cone snails (conotoxin), is the
first FDA approved conotoxin drug used to treat chronic pain in cancer and HIV patients
by targeting voltage-dependent Ca2+ channels. Cone snail toxins have long been
identified as effective compounds for characterizing ion channels and receptors.
However, the Terebridae, a less studied, related venomous snail family, are believed to
be an untapped pharmacologically relevant source of toxins. Similar to cone snails,
genomic and proteomic analyses of terebrid venom reveal a vibrant diversity of peptide
toxins (teretoxins). Here, we present the first structural elucidation of a teretoxin, Tv1.
Tv1 was chemically synthesized, oxidatively refolded, and structurally characterized by
nuclear magnetic resonance (NMR) spectroscopy. Standard homonuclear NMR
methods were used in the structure determination, and the final bundle of lowest energy
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structures revealed an unusual pattern of disulfide bond connectivities potentially unique
to teretoxins. The NMR structure of Tv1 will assist in understanding the toxin's
pharmacological properties, and is being used to guide the search for functional
receptors of Tv1.

2.2 Methods
2.2.1 NMR Solution Structure Derivation
Chemically synthesized and folded Tv1 (79) was obtained from our collaborators
from the Holford group at Hunter College. Toxin samples for Nuclear Magnetic
Resonance (NMR) studies were prepared by dissolving lyophilized oxidized peptide into
either a 9:1 ratio of H2O:D2O or in 100% D2O at a concentration of 260 µM. Sample pH
was adjusted to pH 6.0 and 50 µM trimethylsilyl propanoic acid (TMS) was added as a
reference compound. Spectral acquisition was carried out at 5 ℃ on a Varian Inova 600
MHz NMR spectrometer equipped with a cryogenically cooled HCN probe. 2D-TOCSY
(Total Correlation Spectroscopy) spectra were acquired in 90% H2O (64 scans with
1024x512 points) and D2O (48 scans with 1024x512 points) with spin-lock times of 60
mS, whereas 2D-NOESY (Nuclear Overhauser Spectroscopy) spectra were acquired
with mixing times of 200 mS in H2O with a matrix size of 1024x512 points in 64 scans
and in D2O with a similar matrix size in 112 scans. A natural abundance 1H/13C HSQC
(Heteronuclear Single Quantum Coherence) correlation spectrum was also acquired in
1024 scans with a matrix size of 1024x80 points. Acquired spectra were processed with
NMRPipe (87) and analyzed with CCPNmr Analysis (88). Proton assignments were
made by comparison of TOCSY and NOESY spectra, and used to assign the

13C
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chemical shifts through the HSQC spectrum (Table 1). Distance restraints for structural
calculations were obtained from 2 NOESY spectra: one spectrum collected in 90% H2O
with a mixing time of 200 mS and another spectrum collected in D2O with a mixing time
of 400 mS. Manual assignment was performed for about 90% of all NOE cross-peaks.
Dihedral angle restraints were derived from the assigned chemical shifts using the
software TALOS+ (89). Structural calculations were carried out with ARIA2 (90)/ CNS
(91). Initial structural calculations were conducted using only the manual NOE
assignments (with distances automatically calibrated by the software based on peak
volumes) and without any restraints for the disulfide bonds. An ARIA2 run consisting of
8 iterations of simulated annealing followed by explicit water refinement of the 10
lowest-energy structures was performed. Disulfide connectivities were determined
based on this initial structural bundle and included in the final round of structural
calculations as covalent bonds. Eight iterations were performed in ARIA with 20
structures generated per iteration and the 7 lowest energy structures of each iteration
forming the structural ensemble for the next iteration. For this run, NOE assignments
were allowed to be automatically adjusted by the software during the calculation. For
the last iteration, 100 structures were generated, and ten lowest-energy solutions were
subjected to explicit solvent refinement. The quality of the final structural bundle was
assessed by Procheck NMR (Table 2) (92).

21

2.3 Results and Discussion
2.3.1 Structural Characterization of a Teretoxin by Solution-State NMR
Spectroscopy
Tv1 is a major component of the venom from the terebrid marine snail Terebra
variegata (79). As described in the 2014 paper by Anand et al. (79), venom was
extracted from T. variegata by our collaborators by dissection of the venom glands and
extraction by light sonication into 30% acetonitrile (0.1% TFA), purified by RP-HPLC,
and subjected to de-novo sequencing by ETD- (Electron-Transfer Dissociation) and
CAD- (Collisional Activated Dissociation) MS/MS. Sequencing results yielded a 21
residue peptide (TR(I/L)CCGCYWNGSKDVCSQSCC). Because of their identical
masses, it could not be determined if the amino acid residue at position 3 is an
isoleucine or a leucine. Our collaborators performed bioactivity assays on polychaete
worms which indicated that the isoleucine variant had biological activity. In addition, the
NMR spectra were very similar except for resonances corresponding to isoleucine or
leucine (Figure 2.1). Therefore, all further structural studies were carried out on the
isoleucine variant. We subjected Tv1 to 2D homonuclear TOCSY and NOESY
experiments as well as 2D natural abundance

13C-HSQC.

The TOCSY spectrum was

used to establish amino acid spin systems, while sequential assignments were made
using a TOCSY-NOESY walk, allowing us to assign the proton resonances in both
spectra (Figure 2.2, Table 1). The natural abundance

13C-HSQC

aided in assignment of

the N-terminal threonine since its nitrogen proton correlations were not visible, most
likely due to rapid exchange with the solvent. The HSQC was also used to derive bond
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angle restraints using TALOS+ (89) based on carbon chemical shift assignments (Table
1). Initial structure calculations were carried out without any disulfide bond restraints,
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Figure 2.1: TOCSY comparison of Isoleucine vs Leucine variants of Tv1. An overlay of the
fingerprint region of TOCSY spectra of the Isoleucine variant of Tv1(black) and Leucine variant of Tv1
(blue) shows no major difference between the spectra except for resonances correlated to isoleucine
and leucine, indicating that the overall structure is not affected by this amino acid subsitution.
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and only manually assigned Nuclear Overhauser Effect (NOE) distance restraints. The
proximity of the cysteine residues found in these structures corroborated the mass
spectrometry derived disulfide pattern. Observed NOE connectivities between HN of
Cys16 and the Hα of Cys7 and connectivities to protons in the two flanking residues,
Gly6 and Tyr8, provided further direct evidence of the disulfide bond between residues
Cys7 and Cys16 (Figure 2.3). The final round of structure calculations included the

δ1H (ppm)

TALOS+ derived bond angle restraints, NOE distance restraints, and covalent disulfide

δ1H (ppm)
N
α
Figure
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Figure 2.4: Structure calculation ensemble of Tv1. The ten lowest energy structures of Tv1 are
shown, including only backbone atoms (top) and all atoms (bottom). These structure bundles illustrate
the low RMSD values of 0.42 Å and 0.74 Å for backbone and all heavy atoms, respectively.
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bonds (Cys3-Cys20, Cys4-Cys21, Cys7-Cys16). The 10 lowest energy structures
showed an RMSD of 0.42 Å for backbone atoms, and 0.74 Å for all heavy atoms (Figure
2.4 and Table 2). To determine wether Tv1 shared structural homology with other
peptides we submitted a query using the software packages PDBeFOLD (93) and VAST
(94), which yielded no hits. Tv1’s most prominent and well defined feature is its βhairpin formed between residues 5-10 and 13-18 clamped by the disulfide bridge
formed between cysteines 7 and 16 (Figure 2.5). The fact that structural homology
queries yielded no results indicates that Tv1 may represent a new fold not yet seen in
small peptide toxins, although it does share a cysteine scaffold similar to M Superfamily
Table
statistics
for the
10 models
of Tv1 of Tv1
Table S3.
2.2:Structural
Structural
statistics
forfinal
the final
10 models
Quantity
Total unambiguous distance restraints
Intra residual
Sequential (| i – j | = 1)
Medium (2 ≤ | i – j | ≤ 4)
Long range
NOE violations in all models
> 0.5 Å
> 0.3 Å
> 0.1 Å
RMSD from the average atomic coordinates (Å)
Backbone
Most ordered region (residues 4-18)
All residues
All Atoms
Most ordered region (residues 4-18)
All residues
Deviations from idealized covalent geometry
Bond (Å)
Angles (°)
Improper dihedrals (°)
Ramachandran analysis (%)
Residues in most favored regions
Residues in additionally allowed regions
Residues in generously allowed regions
Residues in disallowed Regions

Value
780
556
73
39
112
0
9
211
0.31 ± 0.10
0.42 ± 0.21
0.59 ± 0.29
0.74 ± 0.43
0.0055 ± 0.0003
0.72 ± 0.045
1.94 ± 0.14
61.2
32.9
5.9
0.0
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conotoxins. The structure of Tv1 is also dominated by tyrosine 8, which anchors a small
hydrophobic core through hydrophobic interactions, namely with isoleucine 3 and valine
15 (Figure 2.5). Observed differences in fold and disulfide pattern are not surprising due
to the lack of sequence homology between M Superfamily conotoxins, even though they
share a similar cysteine scaffolding. M Superfamily conotoxins do not display β-hairpin
folds, leading us to believe that Tv1 is the prototype of a new and unique group of
peptide toxins.

Figure 2.5: Structure of Tv1. Cartoon representation and a stick model of the lowest-energy structure
of Tv1 shows the β-sheet character of the peptide and reveals the important role of the Tyr 8 side chain
in the formation of a small hydrophobic core.
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2.4 Conclusions
Here we present the first structural characterization of a teretoxin described in
the literature. Our collaborators were able to identify the peptide sequence of Tv1 using
4 ng of venom sample from T. variegata. There are over 400 species of terebrids in
nature, and each is believed to express anywhere from 50 to 200 different peptides
within its venom. Using the integrated approach of mass spectrometry to chemical
peptide synthesis to NMR spectroscopy, as was applied to Tv1, it would be possible to
study the structural features of many peptides found in minute quantities in nature,
tapping into this vast pool of teretoxins. The novel structural features of Tv1 suggest that
teretoxins may act by different mechanisms of action and have different cognate
receptors compared to previously described disulfide peptide toxins. If Tv1’s biological
target can be elucidated, this may open the door for sophisticated drug design
experiments. Although the cognate receptor of Tv1 remains elusive, we can formulate a
hypothesis of its mechanism of action based on the structural properties of Tv1. Based
on surface potential calculations, Tv1 has a large positive surface potential with a
protruding Arginine (Figure 2.6). In the literature, pore-blocking toxins have been
described to have a lysine residue protrude into the pore and interact with residues
lining the selectivity filter, occluding the passage of ions (95). If dimensions of the
cognate receptors selectivity filter allows, perhaps Arginine 2 of Tv1 may play the same
role.
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Figure 2.6: Electrostatic surface Potential of Tv1. Electrostatic surface potential of Tv1 showing a
highly dense population of positive charges located on one face of the molecule. Electrostatic surface
potential was generated using the APBS plugin for VMD, using a PQR file generated by the server
PDB2PQR.
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Chapter 3
Expression, Purification, and Preliminary
Characterization of a Human Cardiac Sodium Channel
Voltage-Sensor Domain
Mohammed H. Bhuiyan, Sebastian F. Poget

3.1 Abstract
Voltage-sensor domains (VSDs) of voltage-gated ion channels sense changes in
the membrane potential and as a result alter the conduction state of the channel. The
human voltage-gated sodium channel NaV1.5 is primarily expressed in cardiac muscle
and is responsible for the rising phase of the cardiac action potential. Mutations within
NaV1.5 can lead to fatal cardiac arrhythmias. Such mutations have been found
throughout the gene, including missense mutations within the VSD of repeat IV that
have been shown to lead to Brugada Syndrome and LQT3. The VSDs also play an
important role as the binding sites for gating modifier peptide toxins from tarantula
spider venoms. Such toxins could serve as good lead compounds for drug development
due to their high specificity and subtler mode of action compared to pore blockers.
Therefore, it would be important to know the structures of the human sodium channel
VSDs. While no structures of whole eukaryotic sodium channel proteins exist, isolated
VSDs of other ion channels have been shown to fold into their native conformation in
the absence of the pore forming domain. Therefore, we are pursuing the expression and
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purification of the isolated VSDs of human sodium channels in order to investigate the
structural changes within the VSD caused by pathogenic mutations and by the binding
of gating-modifier toxins. Here, we present the expression in isotopically labeled form
and purification of the human NaV1.5 VSD of repeat IV in a bacterial expression system
and preliminary characterization of the truncated protein. NaV1.5 VSD IV is expressed in
Escherichia coli (E. coli) in minimal media, and extracted from membranes by
solubilization into n-dodecylphosphocholine (n-DPC) micelles. Purified NaV1.5 VSD IV
was characterized by mass spectrometry and gel filtration chromatography and used for
preliminary Nuclear Magnetic Resonance (NMR) structural studies.

3.2 Methods
3.2.1 Cloning of NaV1.5 VSD IV
A synthetic gene coding residues 1512 to 1660 of NaV1.5 was purchased from
GeneWizInc. and named NaV1.5VSDIV (see appendix A1). NaV1.5VSDIV was amplified
by PCR using the primers (Fwd: 5’-CGCGCCATGGGCCGTCCGCTGAACAAGTAC-3’ and Rev: 5’-3’) at final concentration of 0.2 μM, 200 μM

GAGCTCGAGCGACCCACGCGGTACTAAGATGTTGAACAGGGCCGG

dNTPs, 1X standard Taq Reaction Buffer (NEB), 1.25 units of Taq DNA polymerase
(NEB) and less than 1 μg of NaV1.5VSDIV in a 50 μL reaction. The thermocycles were
as follows 95 ℃ for 30 seconds, then 30 repetitions of 95 ℃ for 30 seconds, 51.1 ℃ for
30 seconds, 68 ℃ for 30 seconds, and a final elongation step of 68 ℃ for 5 minutes.
The amplified gene was gel purified using Wizard® SV Gel and PCR Clean-Up System
(Promega) and introduced into pET28b+ expression vector (Novagen) between
restriction sites NcoI and XhoI (pNaV1.5VSDIVsynth coding for NaV1.5 VSD IV-6H). The
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forward primer coding for the restriction site NcoI introduced two residues (Met and Gly)
to the recombinant protein. pNaV1.5VSDIVsynth was subjected to standard PCR
mutagenesis, following the manufacturer’s protocol for QuikChange II XL site- directed
mutagenesis kit (Agilent) to incorporate three codons coding for histidine, extending the
existing histidine tag from six to nine residues (pNaV1.5VSDIVsynth-9H) using the
p r i m e r s ( F w d : 5 ’ - T G G G T C G C T C G A G C AT C AT C AT C A C C A C C A C C A C C - 3 ’ a n d R e v : 5 ’ GGTGGTGGTGGTGATGATGATGCTCGAGCGACCCA

-3’).

3.2.2 Expression Trials of NaV1.5 VSD IV-6H
Expression trials of NaV1.5 VSD IV-6H (encoded in pNaV1.5VSDIVsynth) were
carried out in six E. coli expression cell lines (BL21 (DE3)-AI, BL21 (DE3), BL21 (DE3)pLysS, BL21 (DE3)-pLysS-star, Rosetta (DE3) 2, C43 (DE3)) in 50 mL of rich media in
250 mL autoclaved erlenmeyer flasks. Each expression cell line was tested in various
expression conditions, with variable temperature, Isopropyl β-D-1-thiogalactopyranoside
(IPTG) concentration and time. All cell lines were tested with an induction temperature
of 37 ℃, OD600 of ~1.0, induced for 3 H with either 0.5 mM or 1 mM IPTG; with an
induction temperature of 22 ℃ with an inducer concentration of either 0.5 mM or 1 mM
IPTG upon OD600 reaching ~1.0, with 5 different induction periods (0 H, 2 H, 4 H, 6 H,
and 22 H). Samples of 100 μL were collected, centrifuged at 1180 x g for 5 minutes, and
the supernatant discarded. Western blot analysis (see appendix A2 and A3) showed
Rosetta (DE3) 2 to be the most promising expression strain at 22 ℃. Rosetta (DE3) 2
was then selected for further expression optimization in M63 minimal media (see
appendix A4) at an induction optical density of ~1.0, with various pH’s (6, 7, 8),
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temperatures (37 ℃, 22 ℃, 12 ℃) two inducer concentrations (0.5 mM and 1 mM
IPTG) and variable induction times.

3.2.3 Expression of NaV1.5 VSD IV-9H
Expression of the recombinant protein NaV1.5 VSD IV-9H (NaV1.5 VSD IV
containing a nine residue His-tag separated by a thrombin cleavage site) was carried
out by transformation of the plasmid into the expression cell line Rosetta 2 (DE3)
(Novagen). A liquid culture of the transformed cells was grown overnight at 37 °C in LB
supplemented with 50 µg/mL of kanamycin and 34 µg/mL chloramphenicol. On the
subsequent morning fresh M63 minimal media (pH 6.0) containing 3 g of D-glucose, 50
µg/mL kanamycin, 34 µg/mL chloramphenicol, and 1 g of either

14N-NH4Cl

or

15N-NH4Cl

was inoculated with the overnight culture in a ratio of 1 mL to 50 mL to obtain a starting
OD600 of 0.05-0.1. Inoculated cultures in M63 were grown at 37 °C with shaking at 225
rpm until the OD600 was ~0.7, at which point the temperature was reduced to 12 °C and
shaking increased to 250 rpm until the OD600 reached ~1.0. Protein expression was
induced by the addition of IPTG at final concentration of 1 mM and the cells grown for
an additional 42.5 H.

3.2.4 Isolation of E. coli Membranes
Harvested cells were treated with 5 ml of lysis mixture (50mM sodium phosphate
(NaPi) pH 7.3, 300mM sodium chloride (NaCl), 0.2mg/mL lysozyme, 0.02mg/mL DNase
I, 1mM magnesium chloride (MgCl2), 1mM phenylmethylsulfonyl fluoride (PMSF)) per
gram of wet cell pellet. Resuspended cells were sonicated and centrifuged at 7649.2 x g
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and 4 °C (low speed spin) for 15 minutes to remove non-lysed cells and large cellular
debris. The supernatant was subjected to a second low speed spin. The second
supernatant was then subjected to ultracentrifugation (285000 x g at 4 °C for 90
minutes) to obtain the E. coli membranes. Membrane pellets were stored at -20 °C
when not used.
3.2.5 Detergent Screen
E. coli membranes were resuspended by sonication in resuspension buffer
(50mM NaPi, 300mM NaCl, 1mM PMSF), and aliquoted. Resuspended membranes
were then treated with various detergents (Dodecyl Maltoside (DDM), Decyl Maltoside
(DM), Octyl β-D-galactopyranoside (OβG), Fos-Choline 14 (FC14), Fos-Choline 10
(FC10), n-Dodecylphosphocholine (n-DPC)) at 5% w/v. Detergent extraction was carried
out at room temperature for 2 H, and the extracts were then subjected to centrifugation
at 12557 x g at 4 °C for 20 minutes.

3.2.6 Purification of NaV1.5 VSD IV-9H
Membrane pellets were resuspended by sonication in resuspension buffer to give
a concentration of 100 mg of wet membrane per 1 mL of resuspension buffer.
Resuspended membranes were treated with 2.5% n-DPC for detergent extraction.
Detergent extraction occurred over 2 H at room temperature with gentle rocking. The
extraction solution was then centrifuged at 34541 x g (Sorvall ss-34 rotor) at 4 °C. The
supernatant was then subjected to immobilized metal affinity chromatography (IMAC).
The sample on ice is loaded with a peristaltic pump on to a pre-equilibrated 1 mL GE
TalonTrap (GE Healthcare Life Sciences) (equilibrated with 50mM NaPi (pH 7.3),
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300mM NaCl, 5 mM n-DPC (equilibration buffer)) at a flow rate of 1 mL/minute on ice by
a peristaltic pump (Econo Pump by Bio-Rad). Upon the completion of column loading
the column is attached to a GE AKTA FPLC system (GE Healthcare Life Sciences) and
subjected to the following gradient: 10% elution buffer (equilibration buffer containing
300 mM Imidazole) for 10 minutes, 10%-100% elution buffer over 10 minutes, and
100% elution buffer for 10 minutes; a total run time of 30 minutes. The purification was
fractionated into 1 mL aliquots for the total 30 minute run.
3.2.7 Characterization of NaV1.5 VSD IV-9H
Collected fractions from IMAC purification were analyzed by SDS-PAGE and
those containing the desired protein were pooled, concentrated to ~0.5 mL, and the
imidazole concentration reduced using several concentration-dilution cycles using a
Millipore centrifugal 3 kDa or 30 kDa molecular weight cut off (MWCO) filter with
equilibration buffer as above used for the dilution. Concentrated samples were mixed in
a 1:10 ratio with matrix solution (saturated α-Cyano-4-hydroxycinnamic acid (4-HCCA)
in 3:1:2 formic acid: water: isopropanol), spotted onto a steel target (Bruker) pre-coated
with a thin layer of 4-HCCA (96), and subjected to matrix-assisted laser desorption/
ionization - time of flight (MALDI-TOF) mass spectrometry carried out on a Bruker
Microflex MADLI-TOF mass spectrometer. Samples were also subjected to size
exclusion chromatography on a manually packed Tricorn 10/300 column with Superdex
200 resin (both from GE Health Life Sciences) on a GE AKTA FPLC system, running an
isocratic elution of 50 mM NaPi (pH 7.3), 300 mM NaCl, and 5 mM DPC.
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3.2.8 Toxin Pull down from Crude Gramostola rosea Venom by NaV1.5 VSD IV-9H
Lyophilized venom obtained from Grammostola rosea (G. rosea) by electrostimulation was dissolved in 500 µL of equilibration buffer, treated with pre-equilibrated
Talon Co2+ resin, incubated for 15 minutes and centrifuged at 500 x g. The supernatant
was collected, and the resin washed twice with 750 µL of equilibration buffer. All
supernatants were collected and pooled and will be referred to as pre-depleted venom.
They were split into two 1 mL aliquots and incubated as above with either preequilibrated bare Talon Co+2 resin or NaV1.5-DIV-9His-bound Talon Co+2 resin. The
resins in this case were washed with equilibration buffer containing 20 mM imidazole,
and the washes collected. The resins were then treated with equilibration buffer
containing 500 mM imidazole and collected. All fractions were then analyzed by MALDITOF mass spectrometry.

3.2.9 Reconstitution of NaV1.5 VSD IV-9H into bicelles
The long chain lipid DMPC (Avanti Polar Lipids) dissolved in chloroform was
dried under argon, washed with pentane and dried down with argon 3 times, and placed
under vacuum for 30 minutes to remove residual solvent. Dried DMPC is then
resuspended in 50 mM NaPi (pH 7.3) and 0.025% NaN3 by high power sonication for 30
minutes. NaV1.5 VSD IV-9H dissolved in n-DPC micelles is added to the hydrated
DMPC in a 1:75 protein to long chain lipid molar ratio, and dialyzed extensively against
50 mM NaPi (pH 7.3), 0.05% NaN3. Proteoliposomes are then harvested by
ultracentrifugation (285000 x g at 20°C) and resuspended with DHPC:n-DPC in 300 µL
of 20 mM sodium acetate (NaOAc) (pH ~5), 20 mM NaCl, 10mM dithiothreitol (DTT),
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and 0.05% NaN3 to obtain a final molar ratio of 1:2:1 DMPC:DHPC:n-DPC ratio based
on the initial amount of DMPC in the vesicles. Final ratio of DMPC:DHPC:n-DPC was
analyzed by 1D

31P

NMR on a Varian Inova 300MHz spectrometer at The College of

Staten Island.

3.2.10 Preliminary NMR studies of NaV1.5 VSD IV-9H
15N-NaV1.5

VSD IV-9H was prepared in n-DPC micelles to a concentration of 270

µM in 10 mM NaPi (pH 7.3), 50 mM NaCl, 10% D2O, and 50 µM trimethylsilyl propanoic
acid. This NMR sample was used to collect a

15N-HSQC

at 40℃ (160 scans, 2048x128

points). 15N-TROSY was collected on ~300 µM 15N-NaV1.5-DIV-9His in 300 µL of 20 mM
NaOAc (pH ~5), 20 mM NaCl, 10 mM DTT, 0.05% NaN3 in a 1:2:1 DMPC:DHPC:n-DPC
(10% total lipid concentration), 10% D2O, 10 mM DTT, and 100 μM 4,4-dimethyl-4silapentane-1-sulfonic acid (DSS) at 25 ℃ and 42 ℃. All data acquisitions were
collected on a Varian Inova 600 MHz NMR spectrometer equipped with a HCN cryoprobe. All acquired data were processed with NMRpipe (87) and analyzed with CCPNmr
Analysis (88).

3.3 Results and Discussion
3.3.1 Expression of an isolated NaV VSD
Expression trials of NaV1.5 VSD IV-6H in various E. coli expression strains
(strains listed above) showed no expression at 37 °C by western blot analysis. Since
other groups have had success with expression of mammalian proteins at lower
temperature (81, 97) we decided to carry out further expression trails at 22 °C and 12
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Rosetta 2(DE3) 1.0mM 22 Hrs

Rosetta 2(DE3) 0.5mM 22 Hrs

C43(DE3) 0.5mM 6 Hrs

C43(DE3) 1.0mM 4 Hrs

C43(DE3) 0.5mM 4 Hrs
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C43(DE3) 0.5mM 3 Hrs

Rosetta 2(DE3) 1.0mM 6 Hrs

3hr

3hr

BL21 Star (DE3)plysS 1.0mM 22 Hrs

BL21 Star (DE3)plysS 0.5mM 22 Hrs

BL21 Star (DE3)plysS 0.5mM 6 Hrs

BL21 Star (DE3)plysS 1.0mM 4 Hrs

BL21 Star (DE3)plysS 0.5mM 4 Hrs

C43(DE3) B/I

NaV1.5DIV-6H

Rosetta 2(DE3) 0.5mM 6 Hrs

Rosetta 2(DE3) 1.0mM 4 Hrs

Rosetta 2(DE3) 0.5mM 4 Hrs

Rosetta 2(DE3) 1.0mM 3 Hrs

Rosetta 2(DE3) 0.5mM 3 Hrs

Rosetta 2(DE3) B/I

BL21 Star (DE3)plysS 1.0mM 3 Hrs

aV1.5VSDIV-6H in six different E.coli expression cell lines. Expression conditions being an induction
concentrations of IPTG (0.5mM or 1mM) at 22℃ over 22hrs. Greatest expression was observed in e.coli
s.
NaV1.5DIV-6H

NaV1.5DIV-6H

NaV1.5DIV-6H

Figure 3.1: Expression trials of NaV1.5 VSD IV-6H in six different E. coli expression cell lines.
Western blot analysis of the level of VSD expression was conducted using an anti-His antibody. All
samples were induced at OD600 of ~1.0, using two different inducer concentrations of IPTG (0.5mM or
1mM) and left to express at 22℃ for 22 H. Samples were taken before and 3,4,6 and 22 H after
induction. Greatest expression was observed in E. coli expression cell line Rosetta (DE3) 2 after 22 H.
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Figure 3.1: Expression trials of NaV1.5VSDIV-6H in six different E.coli expression cell lines. Express
OD600 of ~1.0, two different inducer concentrations of IPTG (0.5mM or 1mM) at 22℃ over 22hrs. Greatest
expression cell line Rosetta over 22hrs.

°C. All strains showed expression at 22 °C, with Rosetta (DE3) 2 showing the most
expression (Figure 3.1). Therefore Rosetta 2 (DE3) was selected for further optimization
in minimal media. Expression trials in M63 minimal media were carried out at 22 °C with

Rosetta 2(DE3) 0.5mM 4 Hrs pH 7

Rosetta 2(DE3) 1.0mM 2 Hrs pH 7

Rosetta 2(DE3) 0.5mM 2 Hrs pH 7

Rosetta 2(DE3) B/I pH7

Rosetta 2(DE3) 1.0mM 22 Hrs pH 6

Rosetta 2(DE3) 0.5mM 22 Hrs pH 6

Rosetta 2(DE3) 1.0mM 6 Hrs pH 6

Rosetta 2(DE3) 0.5mM 6 Hrs pH 6

Rosetta 2(DE3) 1.0mM 4 Hrs pH 6

Rosetta 2(DE3) 0.5mM 4 Hrs pH 6

23 kDa

Rosetta 2(DE3) 1.0mM 2 Hrs pH6

Rosetta 2(DE3) B/I pH6

Rosetta 2(DE3) 0.5mM 2 Hrs pH6

varying pH (6, 7, and 8) and inducer concentration (0.5 mM and 1 mM IPTG) for 22 H.

NaV1.5DIV-6H

17 kDa

ell
er

Rosetta 2(DE3) 1.0mM 22 Hrs pH 8

Rosetta 2(DE3) 0.5mM 22 Hrs pH 8

Rosetta 2(DE3) 1.0mM 6 Hrs pH 8

Rosetta 2(DE3) 0.5mM 6 Hrs pH 8

Rosetta 2(DE3) 1.0mM 4 Hrs pH 8

Rosetta 2(DE3) 0.5mM 4 Hrs pH 8

Rosetta 2(DE3) 1.0mM 2 Hrs pH 8

Rosetta 2(DE3) 0.5mM 2 Hrs pH 8

Rosetta 2(DE3) B/I pH 8

Rosetta 2(DE3) 1.0mM 22 Hrs pH 7

Rosetta 2(DE3) 0.5mM 22 Hrs pH 7

Rosetta 2(DE3) 1.0mM 6 Hrs pH 7

Rosetta 2(DE3) 0.5mM 6 Hrs pH 7

Rosetta 2(DE3) 1.0mM 4 Hrs pH 7

H

23 kDa
17 kDa

Figure 3.2: Expression trials in M63 minimal media of NaV1.5 VSD IV-6H in E. coli expression cell
line Rosetta (DE3) 2. Western blot analysis using an anti-His antibody of expression trials in M63
minimal media. Expression was induced at OD600 of ~1.0 with two different inducer concentrations of
IPTG (0.5 mM or 1 mM), and allowed to proceed at 22 ℃ for 22 H at pH 6, 7 and 8. Greatest
expression was observed in M63 minimal media at pH 6 over 22 H.
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Figure 3.3: Expression trials of NaV1.5VSDIV-6H in Rosetta (DE3) 2 in M63 minimal media.
Expression at 22℃ vs 37℃ vs 12℃. Expression conditions being an induction OD600 of ~1.0, two
different inducer concentrations of IPTG (0.5mM or 1mM) at 22℃ over 22hrs or 37℃ at variable time
lengths or 12℃ at variable time lengths. Greatest expression was observed at 22℃ over 22hrs and
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Expression carried out at pH 7 and 8 yielded little to no protein expression when
compared to expression carried out at pH 6 (with different inducer concentrations tested
having almost no effect on the level of protein expression) as determined by western
blot analysis (Figure 3.2). We finally tested expression at 12 °C, similarly to the
expression of the vasopressin V2 receptor (97), in M63 minimal media at pH 6 for 42.5
H with samples collected a various points throughout the growth - 42.5 H being the
optimal time for maximal protein expression (Figure 3.3). The increased protein
production at lower temperatures may be indicative of better protein folding, allowing the
expressed human cardiac VSD to reach the E. coli membranes as opposed to missfolding and being destined for degradation. The ability to express NaV1.5 VSD IV-9H in
an E. coli expression system in minimal media allows for isotopic labeling as was done
by Sander’s group with KCNQ1 VSD (81) and McKinnon’s group with KvAP VSD (28),
paving the way for sophisticated structural studies.

3.3.2 Purification and Characterization of the Human Cardiac VSD IV
Harvested cells containing NaV1.5 VSD IV-9H were lysed, the lysate was cleared
of large debris by slow centrifugation and E. coli membranes harvested by
ultracentrifugation. Membranes were resuspended and the extraction efficiency of
various non-ionic detergents (DM, DDM, OβG), and the zwitterionic detergents (FC10,
FC14, n-DPC) (Figure 3.4) to obtain NaV1.5 VSD IV-9H was tested. NaV1.5 VSD IV-9H
was extracted very poorly in the non-ionic detergents with almost all of the protein found
in the insoluble pellet. In contrast, it was extracted very well in the zwitterionic alkylphosphocholine detergents FC10 and n-DPC (Figure 3.4). For purification purposes,
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FC10 insoluble

FC14 soluble

FC14 insoluble

OβG soluble

OβG insoluble

DM soluble

DM insoluble

DDM soluble

DDM insoluble

Soluble

Insoluble

VSDIV-9H
e (DDM),
holine 10
romise in

Figure 3.4: Detergent screen and extraction trial of heterologously expressed NaV1.5 VSD IV-9H
from Rosetta (DE3) 2 membranes. Six membrane mimetics (n-Dodecyl-β-D-maltopyranoside (DDM),
n-Decyl-β-D-maltopyranoside (DM), Octyl β-D-galactopyranoside (OβG), Fos-Choline 14 (FC14), FosCholine 10 (FC10), n-Dodecylphosphocholine (n-DPC)) were screened for their ability to extract the
VSD from the cell membrane, as detected by western blot analysis of the insoluble and soluble fractions
using an anti-His antibody. n-DPC showed the highest ratio of solubilized to insoluble VSD and was
thus used for extracting NaV1.5 VSD IV-9H from E. coli membranes.

membranes were solubilized and treated with 2.5% DPC for the extraction of NaV1.5
VSD IV-9H. Extracted NaV1.5 VSD IV-9H was then purified by IMAC using GE
TalonTrap Co+2 columns. The resin was treated with a 30 mM imidazole wash to
remove non-specific protein binders, and then treated with a gradient of 30 mM to 300
mM imidazole. NaV1.5 VSD IV-9H eluted from the resin at a concentration of 150 mM
imidazole and showed an apparent mass of ~19 kDa by SDS-PAGE (Figure 3.5).
Pooled fractions were then concentrated to ~500 μL by centrifugal filtration and desalted
by gel filtration chromatography. The size exclusion chromatogram showed an elution
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Figure 5: Purification and SDS-PAGE analysis of NaV1.5-DIV-NonaHis. NaV1.5-DIV-NonaHis was pulled out
from e.coli membranes by IMAC. NaV1.5-DIV-NonaHis was loaded onto a GE TalonTrap Co+2 column and
Figure 3.5:
Purification and SDS-PAGE analysis of NaV1.5 VSD IV-9H. NaV1.5 VSD IV-9H was
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the final 10 minutes. (A) The FPLC chromatogram indicates NaV1.5 VSD IV-9H elutes between
90-150mM imidazole. (B) SDS-PAGE analysis indicates NaV1.5 VSD IV-9H is the major species within
the eluted peak (fractions A15-B12). Black box indicates position of NaV1.5 VSD IV-9H on SDS-PAGE
gel.
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Figure 8: Gel filtration chromatography purification of
NaV1.5-DIV-NonaHis was concentrated into ~500uL and loaded onto GE AKTA FPLC system equipped with
Superdex 200 10/300 GL column. The shoulder of the major peak (fractions A8-A10) containing oligomeric states of NaV1.5-DIV-NonaHis and fractions A11-13 containing monomeric NaV1.5DIV-NonaHis.

Figure 3.6: Gel filtration chromatography purification of 15N-NaV1.5 VSD IV-9H. NaV1.5 VSD IV-9H
was concentrated into ~500uL and loaded onto GE AKTA FPLC system equipped with a Superdex 200
10/300 GL column. Based on NMR analysis, it was found that the shoulder of the major peak (fractions
A8-A10) contains oligomeric states of NaV1.5 VSD IV-9H and fractions A11-13 contain monomeric
NaV1.5 VSD IV-9H.

profile consistent with a particle mass of approximately 60 kDa (Figure 3.6). IMAC and
gel filtration data suggests that the over expressed recombinant protein NaV1.5 VSD
IV-9H is expressed as an embedded integral membrane protein within the E. coli
membrane that can be extracted with detergent and travels as a molecular complex
much larger than the unsolvated VSD when analyzed by gel filtration chromatography.
Furthermore, the fact that the protein is embedded in the E. coli membrane may be
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indicative of a properly folded protein, which eliminates the need for the non-trivial job of
refolding. MALDI-TOF mass spectrometry was used to confirm the presence of NaV1.5
VSD IV-9H in the purified sample and to determine isotope incorporation. The
calculated molecular weight of NaV1.5 VSD IV-9H is 19420.2 Da and we observed a
mass of 19421.8 Da (Figure 3.7A). Additionally, we confirmed that we were able to
isotopically label NaV1.5 VSD IV-9H to a 95.8%

15N

isotopic incorporation (expected

mass: 19657.2 Da; observed: 19646.8 Da) (Figure 3.7B). Although the SDS-PAGE of
purified NaV1.5 VSD IV-9H shows additional bands at higher apparent molecular weight
(30 and 45 kDa), no such species are observable in MALDI-TOF (Figure 3.7A). This
may indicate that those species may be aggregates of NaV1.5 VSD IV-9H. Following the
above protocol, we are able to routinely obtain 1mg of pure, unlabeled VSD starting
from 1 L of growth medium. The ability to produce isotopically labeled VSD will open the
door to future atomic resolution structural and dynamic studies, namely by NMR
spectroscopy (28, 81). By utilizing isotopically labeled VSDs and NMR spectroscopy,
one can potentially characterize the residues involved in toxin binding, and even further
by utilizing various toxins (β-scorpion and spider toxins) one can derive a mechanism of
action for NaV VSDs; as these toxins lock their voltage-sensor in state dependent
manners (45).

3.3.3 Pull down of Novel Site 3 Gating Modifier Toxins
Gating modifier toxins are a known component of tarantula venom. Tarantula
venoms are known to contain both site 3 and site 4 toxins (98, 99, 100, 101). To aid in
the discovery of site 3 toxins, we immobilized NaV1.5 VSD IV-9H on GE TalonTrap and

47

48

Intens. [a.u.]

6471.007

(A)
19421.823

39001.464

Observed: 19421.8

Expected: 19420.2

0

100

200

300

400

(B)
9780.591

19639.226

m/z

Observed: 19639.2

Expected: 19657.2

Figure 3.7: MALDI-TOF analysis of IMAC purified NaV1.5 VSD IV-9H. NaV1.5 VSD IV-9H mixed and crystalized with α-Cyano-4hydroxycinnamic acid (4-HCCA) in formic acid: water: isopropanol (3:1:2) in a 1:9 ratio. (A) The expected mass of NaV1.5 VSD IV-9H is 19420.2
Da, the observed species is 19421.8 Da, with a possible gas-phase dimer observed at 39001.5 Da (expected 38840.4 Da). (B) The expected
mass of 15N NaV1.5 VSD IV-9H is 19657.2 Da, the observed species is 19639.2 Da. 95.8% isotope incorporation is therefore achieved.

Figure 6: MALDI-TOF analysis of IMAC purified NaV1.5-DIV-NonaHis. NaV1.5-DIV-NonaHis mixed and crystalized with α-Cyano-4-hydroxycinnamic acid (4-HCCA) in formic acid:
water: isopropanol (3:1:2) in a 1:9 ratio. The expected mass of NaV1.5-DIV-NonaHis is 19420.2 Da, the observed species if 19421.8 Da, with a possible dimer observed at 39001.5
Figure 9: MALDI-TOF analysis of IMAC purified 15N-NaV1.5-DIV-NonaHis. 15N-NaV1.5-DIV-NonaHis mixed and crystalized with α-Cyano-4-hydroxycinnamic acid (4-HCCA) in formic
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Figure 7: MALDI-TOF analysis of toxin pulldown from Grammostola rosea by NaV1.5-DIV-NonaHis. (A) Pre-depleted venom. (B) 500mM imidazole elution of pre-depleted
venom incubated with pre-equilibrated bare GE Talon Co+2 resin showing two species showing masses of 4067.1 Da and 4102.2 Da (C) 500mM imidazole elution of predepleted venom incubated with pre-equilibrated GE Talon Co+2 resin loaded with NaV1.5-DIV-NonaHis showing two species are pulled down (4069.0 Da andV4103.8 Da)
(D) Overlay spectra of 500mM imidazole fraction of bare resin (red) vs. NaV1.5-DIV-NonaHis bound resin (black), indicating an enrichment of the smaller species by the
presence of NaV1.5-DIV-NonaHis.

Figure 3.8: MALDI-TOF analysis of toxin pull down from Grammostola rosea by Na 1.5 VSD
IV-9H. (A) Pre-depleted venom. (B) 500mM imidazole elution of pre-depleted venom incubated with preequilibrated bare GE Talon Co+2 resin showing two species with masses of 4067.1 Da and 4102.2 Da
(C) 500mM imidazole elution of pre-depleted venom incubated with pre-equilibrated GE Talon Co+2
resin loaded with NaV1.5 VSD IV-9H showing two species are pulled down (4069.0 Da and 4103.8 Da)
(D) Overlay spectra of 500mM imidazole fraction of bare resin (red) vs. NaV1.5-DIV-NonaHis bound
resin (black), indicating an enrichment of the smaller species by the presence of NaV1.5-DIV-NonaHis.

treated the resin with pre-depleted venom obtained from the tarantula Grammostola
rosea. Upon elution of NaV1.5 VSD IV-9H from the resin after treatment with predepleted venom, two species were pulled down from the venom showing masses of
3963.4 Da and 4004.9 Da. Additionally, we also observed an enrichment of the toxin
displaying a mass of 4069.0 Da over the smaller peak at this mass that is also present
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in the control sample (Figure 3.8). Upon searching the data base ArachnoServer (102)
for toxins within ± 10 Da from G. rosea, only two hits were returned (VSTX1:3997.7 Da
and ω-therapohotxin-Gr2a:4073.8 Da), but no exact matches to the observed masses
were found. Employing this method of site 3 gating modifier toxin discovery can open
avenues to toxin characterization and drug development in the treatment of
channelopathies that affect the human cardiac VSD IV, such as LQT3 (103), Brugada
syndrome (104), and progressive familial heart block (105).

3.3.4 NaV1.5 VSD IV-9H Show Enhanced Spectral Quality In Bicelles
15N-isotopically
15N-TROSY

labeled NaV1.5 VSD IV-9H was subjected to 2D-heteronuclear

experiments in either n-DPC micelles or 1:2:1 DMPC: DHPC: n-DPC

bicelles. Upon analysis of the

15N-NaV1.5

VSD IV-9H in n-DPC micelles we saw little to

no signal in the 15N-TROSY experiments, indicating that the protein either takes multiple
conformations that are in intermediate exchange leading to line broadening, or is
aggregating and therefore is forming particles that are too large to be visible by NMR
(Figure 3.9) (gel filtration chromatography indicates the later may be true, data not
shown). Since our lab has had some success in acquiring good spectral data of
NaChBac VSD (Voltage-Gated Sodium Channel of Bacillus halodurans VSD) in bicelles
(unpublished) we tried to use a similar system of NaV1.5 VSD IV-9H in bicelles. We
mixed NaV1.5 VSD IV-9H in n-DPC micelles with DMPC and dialyzed away the n-DPC
to form proteoliposomes. We reconstituted the preoteoliposomes into 1:2:1
DMPC:DHPC:n-DPC bicelles and carried out

15N-TROSY

experiments at 25 ℃ and 42

℃. A great improvement of spectral quality was obtained in bicelles vs micelles (Figure
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3.10). Although the spectral quality increased, the presence of a higher number of
peaks than expected indicates the possible presence of conformational heterogeneity.
One way to confirm and perhaps overcome this is to use toxins known to interact with
VSD IV of NaV1.5 (such as ATX-II, ApA, and ApB) to lock the VSD into one
conformational state.
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maybe

was run on 270 μM 15N-NaV1.5 VSD IV-9H at 40℃ displays spectral broadening and lack of dispersion,
indicating that aggregation may be occurring.
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Figure 3.9: 2-D 15N-TROSY spectra of 15N isotopically labeled NaV1.5 VSD IV-9H. 15N-TROSY of NaV1.5 VSD IV-9H in bicelles (blue and red) and n-DPC micelles (black). The
bicelle sample was run at two different temperatures, 42℃ (red) and 25℃ (blue), while the micelle sample was run at 40℃. Bicelle samples (colored) show vast improvement in
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Figure 3.10: 2-D N-TROSY spectra of N isotopically labeled Na 1.5 VSD IV-9H. N-TROSY of
300 μM NaV1.5 VSD IV-9H in bicelles (blue and red) and n-DPC micelles (black). The bicelle sample
was run at two different temperatures, 42℃ (red) and 25℃ (blue), while the micelle sample was run at
40℃. Bicelle samples (colored) show vast improvement in signal compared to the micelle sample
(black).
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3.4 Conclusions
Structural studies are severely lacking in the realm of mammalian NaVs, and only
a few structures of bacterial NaVs channels exist to date (32, 33, 34, 106). This is in
significant part due to the large structure and complexity of mammalian NaVs. One way
to overcome this problem is to express portions of individual subunits to vastly reduce
the size and complexity for structural studies by methods such as NMR. Here we have
shown that we can express a human cardiac voltage-gated sodium channel VSD in a
bacterial expression system in milligram quantities. This provides us with the ability to
isotopically label NaV1.5 VSD IV-9H, which is necessary to conduct NMR based
structural analysis as has been demonstrated for VSDs from KVAP(28) and KCNQ1
(81). Recombinant protein expression also allowed us to incorporate a 9 residue His-tag
allowing for IMAC purification. Furthermore, by immobilizing the VSD of interest to a
metal affinity resin we were able to pull down a potentially novel toxin from the venom of
G. rosea. The binding of this novel toxin to NaV1.5 VSD IV suggests that it is a site 3
gating modifier toxin and would most likely inhibit or slow fast inactivation, though more
studies are needed to confirm this hypothesis. This method of toxin discovery will aid in
the growing field of venomics and produce lead compounds for drug design targeted
toward NaVs as seen with CaV inhibitor Ziconitide (107). Furthermore, structural studies
of these neurotoxins in complex with VSDs may lead to a better understanding of the
mechanism of action of toxin activity and voltage gating given the fact that these toxins
bind to VSDs in state specific manners.
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Chapter 4
Chemical and Biological Synthesis of the Human
Cardiac Sodium Channel Voltage-Sensor Domain IV
Paddle Motif
Mohammed H. Bhuiyan, Adel K. Hussein, Boris Arshava, Jianqin Zhuang, Fred Naider,
Sébastien F. Poget

4.1 Abstract
Voltage-gated sodium channels (NaVs) are membrane proteins that serve
important functions in the central and peripheral nervous systems (C/PNS) and cardiac
and skeletal muscle. NaVs participate in the regulation of the membrane potential across
the plasma membrane of excitable cells and are involved in the depolarization process.
Currently there are nine subtypes of NaVs that have been characterized to date, Nav1.1
– Nav1.9. The nine subtypes are expressed in a tissue specific manner, each with
unique gating properties. Numerous channelopathies have been linked to defects in
NaVs including epilepsy, mental retardation, and several ailments that could lead to
sudden heart death. Interestingly, the primary target of peptide toxins from venomous
and poisonous animals are VGICs, encompassing NaVs. These toxins have been used
as excellent probes for the identification and functional characterization of NaVs due to
their specific and potent effect. By solving the structural details of the interaction
between animal peptide toxins and NaVs we will gain more insight into the function of
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these channels. However, probing these interactions at the atomic level proves to be
difficult as NaVs are large (200 kDa), highly hydrophobic, flexible and difficult to purify
proteins. This makes it unlikely that X-ray crystallography, solution-state NMR or cryoEM would be successful. As an alternative strategy to overcome the difficulties NaVs
pose to us, we will study a common peptide toxin binding motif, the S3b-S4 paddle motif
in complex with an interacting toxin. The Nav1.5 DIV S3b-S4 paddle motif is a small
portion of the channel that has been shown to interact with α-scorpion and sea
anemone toxins, which inhibit the channels’ ability to fast inactivate. We have
synthesized the paddle motif chemically and biosynthetically through Fmoc solid phase
peptide synthesis and recombinant expression, respectively. Furthermore, we have
characterized the paddle motif through circular dichroism, UV spectroscopy and
solution-state NMR experiments.

4.2 Materials and Methods
4.2.1 Design of NaV1.5 DIV S3-S4 Paddle Motif
Using the sequence alignment tool, T-Coffee (108), the complete S3 and S4
transmembrane domains and the connecting loop of NaV1.5 DIV, as defined by
UniProt(109), was aligned with the S3-S4 paddle motif of Nav1.2 VSD IV used by
Martin-Eauclaire et al. (26) in their SPR experiments. We also modeled the same
sequence of residues used in our sequence alignment using Swiss-Model (110).
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4.2.2 Chemical Synthesis and Purification of NaV1.5 DIV S3-S4 Paddle Motif
The 37 residue NaV1.5 DIV S3-S4 paddle motif was chemically synthesized
using 0.1 mMol fast Fmoc solid phase peptide chemistry on a Applied Biosystems 433A
synthesizer. The synthesis was carried out on the 0.1 mMol scale using Fmoc-Ile Wang
resin (0.5 mMol/g). The side chain protected amino acids used were Fmoc-Arg(Pmc),
Fmoc-Thr(tBut), Fmoc-Ser(tBut), Fmoc-Lys(Boc), Fmoc-Gln(Trt), and Fmoc-Asp(OtBu).
All amino acids were attached using single coupling. Upon completion of the synthesis
the peptidyl resin was cleaved at room temperature with a cleavage cocktail (95%TFA,
2.5% H2O, 2.5% Triisopropylsilane) for 105 minutes and filtered. The filtrate was
concentrated on a rotary evaporator under vacuum and precipitated with cold ehtylether and dried. The crude peptide was dissolved in 50% TFE and 50% buffer A (H2O,
0.1% TFA) and purified on an Agilent 1100 series RP-HPLC running a 20-90% gradient
with increasing buffer B (Acetonitrile, 0.1% TFA) over 60 minutes at 50℃ using a
preparative Agilent Zorbax 300SB C3 column (21x150 mm) with inverted flow. The final
yield of the synthesis was 28% of the correct peptide in the crude peptide by RP-HPLC.
Peptide purity was analyzed by injection onto an Agilent 1100 series RP-HPLC
equipped with an Eclipse XDB-C8 column with inverted flow, running a gradient of
20-90% increasing buffer B over 20 minutes at 50 ℃.

4.2.3 Plasmid design of TrpΔLE-NaV1.5 DIV S3-S4 Paddle Motif
The DNA sequence coding for the 37 residue peptide was cloned from
pNaV1.5DIVsynth using standard PCR techniques with the primers (Fwd: 5’GGGAAGCTTTGGATGGTGGTTGTGATCCTGAGCATC

-3’ and Rev: 5’-CGGGGATCCTCAGATACGGCCGATGCGG-3’) and
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purified using the QIAquick PCR Purification Kit (Qiagen). PCR amplified DNA and
pMMHa(111) obtained from the Naider lab were cleaved with the restriction enzymes
HindIII (NEB) and BamHI (NEB) following NEB’s recommended conditions for 2 H at 37
℃. Both DNA products were gel purified using the QIAquick Gel Extraction Kit (Qiagen).
The digested PCR insert was ligated into the digested pMMHA plasmid in a 3:1 molar
ratio using Instant Sticky-end Ligase Master Mix (NEB) and transformed into NEB® 5alpha competent E. coli (NEB). Plasmid DNA was isolated from 5 ml overnight LB
cultures of transformed cells using the QIAprep Spin Miniprep Kit (Qiagen) and sent for
sequencing at GeneWizInc. using a T7 promoter sequencing primer. We performed
sequence analysis using Serial Cloner (Serial Basics) and confirmed the insertion of the
NaV1.5 DIV S3-S4 paddle Motif into pMMHa to obtain the plasmid pNaV1.5IVPM.

4.2.4 Biosynthesis and Purification of NaV1.5 DIV S3-S4 Paddle Motif
pNaV1.5IVPM was transformed into the E. coli expression cell strain C43 (DE3).
M63 minimal media (pH 7) (supplemented with 3g/L of
and 1 g/L

14N-NH4Cl

or

15N-NH4Cl)

12C-D-glucose

or

13C-D-glucose

was inoculated with 20 mL of overnight LB cultures

of pNaV1.5IVPM transformed C43 (DE3) and grown at 37 ℃ with shaking at 250 rpm.
Upon OD600 reaching 0.4, the culture was induced with IPTG (1 mM final concentration)
and grown for an additional 22 H. Cells were harvested by centrifugation (4 ℃ and 4000
rpm for 20 minutes). All of the following steps were carried out on ice unless otherwise
stated. Harvested cells were resuspend in lysis mix (50 mM Tris-HCl (pH 8), 1 mM
EDTA, 1 mM PMSF, 0.3 mM lysozyme) and sonicated in a cup sonicator and
centrifuged at 18,000 rpm for 20minutes in an SS-34 rotor. The supernatant was
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discarded and the pellet was resuspended in lysis buffer (50 mM Tris-HCl (pH 8), 1 mM
EDTA) by sonication, and centrifuged as stated in the previous step. Once again the
supernatant was discarded and the pellet resuspended in mild detergent (1% igepal
Ca-630 and 1% deoxycholic acid in lysis buffer) by sonication and centrifuged. The
pellet generated after treatment with mild detergent was then resuspended in water to
remove any residual detergent, and centrifuged. Finally the last pellet was resuspended
in water and aliquoted into 1 mL fractions and centrifuged for 60 minutes at 14,800 rpm.
Pellets were stored at -20 °C until needed. Three pellets were dissolved into 1 mL of of
binding buffer (8 M urea, 500 mM NaCl, 20 mM NaPi (pH 7.3), 2% sarcosine); and
sonicated to clarify the solution if necessary. The dissolved pellets were then incubated
with 0.25 mL of Ni Sepharose 6 Fast Flow (GE healthcare) that was pre-equilbrated with
binding buffer following the manufactures protocol and incubated for 1 hour at room
temperature with gentle rocking. After incubation, the resin and fusion protein solution
were transferred to a Poly-Prep Chromatography Column (Bio-Rad), and washed twice
with 4 column volumes of binding buffer. The fusion protein was then eluted from the
resin with 4 column volumes of elution buffer (500 mM NaCl, 500 mM imidazole, 20 mM
NaPi (pH 7.3), 2% sarcosine). The eluted sample was then dialyzed extensively in water
to induce precipitation and lyophilized. The lyophilized fusion protein was then dissolved
in 700 μL of 100% TFA by sonication and diluted to 70% TFA with water. The dissolved
fusion protein was then treated with 100 mg of cyanogen bromide (CNBr) and cleaved
for 2.5 H at room temperature in the dark. The cleavage mixture was then injected onto
an Agilent 1100 series RP-HPLC running a 20-90% gradient with increasing buffer B
(Acetonitrile, 0.1% TFA) over 60 minutes at 50℃ using a preparative Agilent Zorbax
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300SB C3 column (21x150 mm) with reversed flow direction for purification, and the
fractions containing NaV1.5 DIV S3-S4 paddle motif were pooled and lyophilized. The
identity and isotope incorporation of the purified paddle motif were determined by
MALDI-TOF using a Bruker MicroFlex MALDI-TOF spectrometer. Samples for MALDITOF were prepared following the protocol by Chait’s group(96).

4.2.5 Solution-State NMR of the NaV1.5 DIV S3-S4 Paddle Motif
RP-HPLC purified NaV1.5 DIV S3-S4 paddle motif was dissolved in 10mM
potassium phosphate (pH 7), 10 mM NaCl, 50 µm DSS, 10% D2O and either 50 mM nDPC or Fos-Choline 10 (FC10). All spectral acquisition was carried out at 37 ℃ on a
Varian Inova 600 MHz NMR spectrometer equipped with a cryogenically cooled HCN
probe at The College of Staten Island. The unlabeled peptide (14N/12C) was subjected to
homonuclear 2D-TOCSY and 2D-NOESY at a total peptide concentration of 1 mM. 500
μM

15N/13C

labeled paddle was subjected to HNCO and HN(CO)CA 3D experiments on

a Bruker AVANCE III HD 800 MHz NMR spectrometer equipped with a 5-mm TCI
cryoprobe at the CUNY Advanced Science Research Center. HNCA and HNCACB 3D
experiments were collected on a Bruker AVANCE III HD 700 MHz NMR at the New York
Structural Biology Center. For toxin interaction studies a 500 μM

15N

labeled paddle

sample was diluted 8-fold and its HSQC spectrum recorded both before and after the
addition of ApA toxin to a final concentration of 17.3 μM at The College of Staten Island.
Peptide concentrations were determined by mass, as NaV1.5 DIV S3-S4 paddle motif
does not contain tryptophan residues. All processing was done with NMRPipe (87) and
analyzed with CCPNmr Analysis (88).
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4.3 Results and Discussion
4.3.1 Defining the Human Cardiac NaV DIV S3-S4 Paddle Motif
We used the NaV1.2 DIV S3-S4 paddle motif used by Martin-Eauclaire et al.(40)
in their elegant surface plasmon resonance studies as template for sequence alignment
of the NaV1.5 S3-loop-S4 sequence. This choice was based on the fact that MartinEauclaire et al. showed that their 32 residue peptide is sufficient for binding of site 3
gating modifier toxins in SPR experiments. We aligned our S3-loop-S4 sequence
fragment as defined by UniProt (109) with the Martin-Eauclaire et al. peptide using the
software T-Coffee (108). The T-Coffee sequence alignment shows good agreement
between the two sequences due to the high homology between the two paddle motifs
(Figure 4.1). The results from Swiss-Model (110) modeling of the S3-loop-S4 fragment
showed that this sequence is likely to adopt a helix loop helix hairpin motif, helping us to
further refine the final sequence we used for all further experiments (Figure 4.2) Based
on the alignment and modeling data we decided to include 5 more residues to the Nterminus of the NaV1.5 DIV S3-S4 paddle motif compared to the NaV1.2 DIV S3-S4

Figure 4.1: Sequence alignment of paddle motifs of neuronal and cardiac NaV. The 32 residue
NaV1.2 DIV S3-S4 paddle motif shown to bind site 3 toxins aligned with NaV1.5 DIV S3 transmembrane
domain - extracellular loop - S4 transmembrane domain. Alignment show good homology. “*”
representing identical residues, “:” representing residues of the same hydropathy and size, and “.”
representing similar size or hydropathy.
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paddle motif to help stabilize the
peptide in a helix loop helix
hairpin motif conformation,
therefore the resulting peptide
consists of 37 residues from
Valine1597 to Isoleucine1634 out
of the full 2016 residue NaV1.5
protein.

Figure 4.2: Model of An Isolated Human Cardiac NaV S3S4 Paddle Motif. The 56 residues coding for NaV1.5 DIV’s S3
transmembrane domain - extracellular loop - S4
transmembrane domain was model by Swiss-Model using
PDB structure 3LUT as a template. Here we show only the 37
residues used for all subsequent experiments. Gating
Arginines shown in blue.

4.3.2 Purification of a Chemically Synthesized Isolated Human Cardiac NaV S3-S4
Paddle Motif
We chemically synthesized NaV1.5 DIV S3-S4 paddle motif using standard Fmoc
solid phase peptide synthesis and the major product was found to be the correct peptide
(Figure 4.3A). The unlabeled peptide was purified to 98% purity by RP-HPLC (Figure
4.3B) NaV1.5 DIV S3-S4 paddle motif elutes at 72.5% buffer B (acetonitrile) indicating it
has a high hydrophobic character. Maldi-TOF analysis confirmed the correct peptide
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Data File C:\HPCHEM\1\DATA\BORIS\08241500.D Sample Name: Nav1.5 D4S3S4Lin
Instrument 1 8/24/2015 4:25:28 PM Boris
Nav1.5 D4 S3-S4-Linker crude peptide 1/2 cleaved, -> 285 mg. in 50% TFE/water+, 10ul
injected. 20-90% ACN+, 20 min, +50 oC 220nm. Zorbax Ding's Reverse Eclipse XDB-C8 S/N
USRK060104. 06052015
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20-90% at 20min 1 ml/min ACN gradient, +40oC 220nm
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300
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2 14.750 VV
0.1521 256.80585
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0.2012 3532.34375 261.69214 29.3941
410015.514 VV
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min

Ar 14.967
ea
:2
39
4.
13

15.785
16.154

250

Signal 1: VWD1 A, Wavelength=220 nm

17.5

A14.798
re
a:
28
.0
07
6

(B)

14.750

A11.109
re
a:
31
63
.7
4

=====================================================================
150
Injection Date : 8/26/2015 6:01:47 PM
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: 8/26/2015 6:00:16 PM by Boris
Analysis
Method : C:\HPCHEM\1\METHODS\2090I20.M
0
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=====================================================================
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=====================================================================
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Nav1.5
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Figure 4.3: RP-HPLC Analysis of crude and purified NaV1.5 DIV S3-S4 paddle motif. (A) Analysis of
By
:
Signal
crude NaSorted
V1.5 DIV S3-S4 paddle motif on an Agilent 1100 series HPLC running 20-90% buffer B at 50℃
Multiplier
:
1.0000
over 20 Dilution
minutes eluting at 72.5% :buffer B1.0000
showing 29% purity and indicating it is the major product. (B)
AnalysisUse
of purified
NaV1.5
S3-S4Factor
paddle with
motif ISTDs
indicating 98% purity was obtained after preparative
Multiplier
& DIV
Dilution
RP-HPLC purification.
Signal 1: VWD1 A, Wavelength=220 nm
Peak RetTime Type Width
Area
Height
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#
[min]
[min] mAU
*s
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]
%
----|-------|----|-------|----------|----------|--------|
1 14.798 MF
0.0806
28.00762
5.78846
1.1563
2 14.967 FM
0.2181 2394.13306 182.97887 98.8437
Totals :
2422.14067 188.76733
=====================================================================
*** End of Report ***
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Figure 4.4: MALDI-TOF Analysis of crude and purified NaV1.5 DIV S3-S4 paddle motif. NaV1.5 DIV
S3-S4 paddle motif was mixed and crystalized with α-Cyano-4-hydroxycinnamic acid (4-HCCA)
saturated in either formic acid: water: isopropanol (3:1:2) or acetonitrile (0.1% trifluoroacetic acid): water
(0.1% trifluoroacetic acid) (2:1) in a 1:9 ratio. The expected mass of NaV1.5 DIV S3-S4 paddle motif is
4204.1 Da, observed mass is 4205.1 Da.
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4.3.3 Biosynthesis and Purification of An Isolated Human Cardiac NaV S3-S4
Paddle Motif
Due to the inherently large concentration of detergent molecules in micelles
(FC10 and n-DPC) that would hinder future structural studies by homonuclear NMR, we
moved forward in isotopically labeling NaV1.5 DIV S3-S4 paddle motif through bacterial
expression. We cloned the paddle motif using our synthetic VSD gene
pNaV1.5VSDIVsynth-NH, as a template into the plasmid pMMHa (111) using standard
molecular biology techniques. This plasmid has been shown in the past to direct
membrane protein fragments into inclusion bodies due to the TrpΔLE fusion protein
fragment (112-114). Since NaV1.5 DIV S3-S4 paddle motif does not code for any
endogenous Methionine residues, expression as a TrpΔLE fusion protein is suitable for
CNBr cleavage from TrpΔLE without the incorporation of non-endogenous residues.
Expression of the TrpΔLE-NaV1.5 DIV S3-S4 paddle motif fusion protein was carried out
in M63 minimal media (containing isotopically enriched

15NH4Cl

and

13C

glucose) in the

expression cell strain C43 (DE3) at 37 ℃ for 22 H post induction with 1 mM IPTG.
Inclusion bodies were isolated as was done in (113). We tried to clean up the inclusion
bodies by batch-wise IMAC purification through the TrpΔLE’s hexa-Histidine tag, but
this did not significantly improve the purity of the TrpΔLE-NaV1.5 DIV S3-S4 paddle
motif as multiple protein bands can be seen co-eluting with it by SDS-PAGE analysis
(Figure 4.5). Fractions containing the TrpΔLE-NaV1.5 DIV S3-S4 paddle motif were
dialyzed extensively to remove any salts and detergent and lyophilized. TrpΔLE-NaV1.5
DIV S3-S4 paddle motif was then solubilized in 70% TFA and reacted with CNBr to
cleave the peptide from the fusion protein, and subjected to RP-HPLC (Figure 4.6).
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Although CNBr cleavage in TFA was of low efficiency, attempts to optimize in formic
acid showed similar results. The isotopically double labeled (15N/13C) paddle was
obtained and the correct size of the construct confirmed by MALDI-TOF analysis (Figure
4.7).

22kDa

700 mM

500 mM

400 mM

200 mM

100 mM

Wash

Flowthrough

12kDa

Figure 4.5: Purification and SDS-PAGE analysis of TrpΔLE-NaV1.5 DIV S3-S4 paddle motif fusion
protein. TrpΔLE-NaV1.5 DIV S3-S4 paddle motif fusion protein was subjected to batch-wise IMAC
purification using Ni+2-NTA resin where the majority of the protein elutes at a imidazole concentration of
200mM to 400mM. TrpΔLE-NaV1.5 DIV S3-S4 paddle motif protein band is enclosed by black box.
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FP

PM

Figure 4.6: RP-HPLC purification of CNBr Cleave of TrpΔLE-NaV1.5 DIV S3-S4 paddle motif fusion protein. Cleavage reaction was run on
an Agilent 1100 series HPLC running 20-90% buffer B at 50℃ over 60 minutes eluting at 67% buffer B. Three major peaks are visible, the
Figure 4.6:
RP-HPLC
purification
of CNBr Cleave
of TrpΔLE-NaV1.5 DIV S3-S4 paddle motif fusion protein. Cleavage reaction was run on
TrpΔLE
fusion
partner (TrpΔLE),
TrpΔLE-Na
V1.5 DIV S3-S4 paddle motif fusion protein (FP), and NaV1.5 DIV S3-S4 paddle motif (PM).
an Agilent 1100 series HPLC running 20-90% buffer B at 50℃ over 60 minutes eluting at 67% buffer B. Three major peaks are visible, the
TrpΔLE fusion partner (TrpΔLE), TrpΔLE-NaV1.5 DIV S3-S4 PM fusion protein (FP), and NaV1.5 DIV S3-S4 PM (P).

TrpΔLE

Figure 4.7: MALDI-TOF Analysis of purified NaV1.5 DIV S3-S4 paddle motif. NaV1.5 DIV S3-S4
paddle motif was mixed and crystalized with α-Cyano-4-hydroxycinnamic acid (4-HCCA) saturated in
either formic acid: water: isopropanol (3:1:2) or acetonitrile (0.1% trifluoroacetic acid): water (0.1%
trifluoroacetic acid) (2:1) in a 1:9 ratio. The expected mass of 15N/13C-NaV1.5 DIV S3-S4 paddle motif is
4454.1 Da, observed mass is 4412.6 Da showing an isotope incorporation of 83.1%.

4.3.4 Structural Studies of the Human Cardiac NaV1.5 DIV S3-S4 Paddle Motif
Initially we dissolved NaV1.5 DIV S3-S4 paddle motif in NMR buffer (10 mM KPi
10 mM NaCl, 50 µM DSS) containing 50 mM or 100 mM n-DPC for initial TOCSY and
NOESY experiments based on the successful extraction of the entire NaV1.5 VSD IV-9H
from E. coli membranes by n-DPC. The spectral quality of the peptide in 50 mM and
100 mM n-DPC left much to be desired as little signal was obtained. This could be due
to the fact of n-DPC’s large aggregation number of 54 molecules per empty micelle,
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leading to slower tumbling of the petidyl-micellular complex and increased line
broadening. Therefore, we investigated using FC-10, which retains the head group of nDPC, but with a smaller alkyl chain of 10, and a much smaller aggregation number of
24. 2D homonuclear TOCSY and NOESY experiments were then performed on the
peptide in 50 mM FC10, which yielded marked improvement in spectral quality (Figure
4.8). Though FC10 showed promise, it also had drawbacks, due to the high
concentration of detergent molecules it produced large signal in the aliphatic region,
making side chain assignments of NaV1.5 DIV S3-S4 paddle motif impractical (Figure
4.8). Since deuterated n-DPC is not readily available (as a custom synthesis was
quoted at $15,000), we decided to isotopically label the peptide (Figure 4.9) and utilize
standard 2D- and 3D-heteronuclear techniques to make backbone assignments. The
2D-

15N-HSQC

shows good spectral dispersion indicating the peptide is well behaved

and folded (as corroborated with CD analysis showing one maximum at 190 nm and two
minima at 208 nm and 220 nm, which is characteristic of α-helical peptides/proteins
(Figure 4.9)) (Figure 4.10). We then proceeded to run all the necessary triple resonance
experiments for backbone assignments, HNCO, HNCA, HNCOCA, and HNCACB. We
were able to assign 86% of the theoretically observable residues (Table 4.1) using an
HNCOCA/HNCA walk (Figure 4.11) and confirming connectivities with the aid of the
HNCACB. Chemical shift index analysis of NaV1.5 DIV S3-S4 paddle motif’s C, Cα, and
Cβ chemical shifts predict two α-helical regions (Figure 4.12), corroborating both the
predicted S3 and S4 transmembrane domains defined by Uniprot and the α-helical
character predicted by CD analysis.
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Figure 4.8 2-D Homonuclear TOCSY spectra of NaV1.5 DIV S3-S4 paddle motif. Fingerprint region
of 1 mM NaV1.5 DIV S3-S4 paddle motif shown in (A) 50mM n-DPC (blue), (B) 100mM n-DPC (black),
and (C) 50mM FC10. (D) Aliphatic region of 1 mM NaV1.5 DIV S3-S4 paddle motif in 50mM FC10.
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Figure 4.9: Circular Dichroism (CD) of NaV1.5 DIV S3-S4 paddle motif. CD analysis of the NaV1.5
DIV S3-S4 paddle motif in n-DPC (grey) and FC10 (blue) show a maxima at 190nm and two minima at
208nm and 220nm indicating the peptide take an α-helical secondary structure.
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Figure 4.10 2-D 15N-HSQC spectra of 15N/13C isotopically labeled NaV1.5 DIV S3-S4 paddle motif.
HSQC shows a well dispersed peptide indicating the protein may be adopting a folded conformation. Of
the 36 observable amide protons (proline doesn't have an observable amide proton), 31 correlations are
observed, with two side chain amine correlations.
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Table 4.1:
Chemical
shift assignments
NaV1.5
DIV S3-S4
motif (in ppm)
Table 4.1: Chemical
shift
assignments
of NaV1.5 DIVof
S3-S4
paddle
motif paddle
(in ppm)
H

H
N

Cαβ

Cβ

177.21
61.78

61.78
29.25

29.25

N
C

CCα
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176.77
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1

Val

1
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2

Val
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1
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1
77.19

77.19
60.65

60.65
35.18

35.18

Leu

5

Leu

5
8.25

8.25
120.53

120.53
178.48

178.48
55.09

55.09
38.86

38.86

Ser

6

Ser

6
8.03

8.03
113.80

113.80
176.34

176.34
58.65

58.65
60.15

60.15

Ile

7

Ile

7
7.75

7.75
121.27

121.27
177.50

177.50
61.39

61.39
35.84

35.84
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Gly
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Gly
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56.64
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Figure 4.11: 3-D HNCOCA/HNCA spectra of 15N/13C isotopically labeled NaV1.5 DIV S3-S4 paddle motif. Five residue sequential HNCOA/HNCA walk depicted shown how back bone assignments were
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4.3.5
Interactions
of the Human Cardiac NaV1.5 DIV S3-S4 Paddle Motif
∆δ(

1

H

α

)
Upon
assignment of the NaV1.5 DIV S3-S4 paddle motif we wanted to probe the

structural interactions in the presence of a gating-modifier. We selected the sea
anemone gating-modifier toxin ApA as it is a known site 3 toxin(65) and our lab has the
ability to biosynthesize and correctly fold this toxin (though not in great yields). We
recorded the

15N-HSQC

of an 8-fold diluted sample in the presence and absence of the

gating-modifier toxin ApA. Although the diluted sample yielded a weak signal most of the
peaks were still present, but interestingly upon the addition of toxin the signal was
absent (Figure 4.13). To determine what was the cause of the lack of signal we took the
NMR sample of the paddle in the presence of toxin and carried out MALDI-TOF and UVVis spectroscopy to determine if the paddle was still present and it concentration.
MALDI-TOF analysis indicated that upon the addition of ApA the paddle remained in
solution (Figure 4.14) and UV-Vis indicated a paddle peptide concentration of ~117 μM
(though this may not be accurate as NaV1.5 DIV S3-S4 paddle motif does not contain a
Tryptophan residue). Based on both the MALDI-TOF and UV-Vis spectroscopy data
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indicating the paddle and toxin remained in solution points to the lack of signal in the
15N-HSQC
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Figure
4.13 2-D 15N-HSQC spectra of 15N isotopically labeled NaV1.5 DIV
S3-S4 paddle motif in the
Figure 4.12 2-D 15N-HSQC spectra of 15N isotopically labeled NaV1.5 DIV S3-S4 paddle
motif in the absence and presence
15N/13C isotopically labeled
absence
and
presence
of
ApA.
HSQC
spectra
of
(A)
non-diluted
500
μM
of ApA. HSQC shows a well dispersed peptide indicating the protein may be taking a fold. Of the 36 observable Amide protons
(Proline doesn't
observable
amide
proton)
31 correlations
are(B)
observed,
with15two
side chain amine
correlations.
peptide
in 50 have
mM an
FC10
sample
in the
absence
of ApA,
500 μM
N isotopically
labeled
peptide in 50
mM FC10 sample diluted 8-fold in the absence of ApA, and (C) 500 μM 15N isotopically labeled peptide
in 50 mM FC10 sample diluted 8-fold in the presence of 17.3 μM ApA showing complete loss of signal
indicating an interaction.
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Figure 4.14: MALDI-TOF Analysis of 15N-NaV1.5 DIV S3-S4 paddle motif NMR sample in the
presence of ApA. The paddle-toxin NMR sample was mixed and crystalized with α-Cyano-4hydroxycinnamic acid (4-HCCA) saturated in acetonitrile (0.1% trifluoroacetic acid): water (0.1%
trifluoroacetic acid) (2:1) in a 1:9 ratio. The expected mass of 15N-NaV1.5 DIV S3-S4 paddle motif is
4255.1 Da, observed mass is 4255.3 Da, and the expected mass of ApA is 5131.7, observed mass is
5132.3.

hydrophobic portions the NaV1.5 DIV S3-S4 paddle motif causing the peptides to form
large soluble aggregates that may be invisible to solution-state NMR.

4.4 Conclusions
As of this writing, there have been no structural studies of isolated mammalian
NaV paddle motifs and only one structurally characterized isolated KV paddle motif
(115). Moreover, previous research has indicated that transplanted and isolated paddle
motifs retain sufficient information to recognize and bind toxins (26, 40). Here we
present the structural characterization of the paddle motif of DIV of the human cardiac
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sodium channel. We were able to biosynthesize the NaV1.5 DIV S3-S4 paddle motif of
DIV in isotopically labeled form in E. coli, allowing us to make back bone assignments to
86% completion. The HSQC indicates that the NaV1.5 DIV S3-S4 paddle motif is a well
behaved structured peptide, although upon addition of a site 3 getting-modifier toxin
(ApA) known to interact with NaV1.5 the HSQC signal is undetectable. MALDI-TOF and
UV-Vis spectroscopy indicated the paddle and toxin remained in solution, supporting the
hypothesis that lack of signal in the NMR experiment is due to an interaction between
the two. We can perform isothermal calorimetry (ITC) or SPR to study the interaction
between the two peptides and derive the KD. If we hope to structurally characterize the
interaction we need overcome this lack of NMR signal. Experiments such as gel
filtration chromatography and multi angle light scattering will give insights to the both the
molecular weight and size (respectively) of the NaV1.5 DIV S3-S4 paddle motif before
and after treatment with ApA. If ApA is causing soluble aggregates invisible to solutionstate NMR, solid-state NMR could be an alternative probing the interactions. NMR
conditions (salt, pH, temperature) could also be adjusted in an effort to improve
solution-state signal acquisition. Also based on the SPR studies done with the NaV1.2
DIV S3-S4 paddle motif by Martin-Eauclaire et al.(40) one could further this concept by
immobilizing the paddle motifs on a resin to perform affinity chromatography on various
venoms to aid in toxin discovery specifically site 3 gating-modifier toxins. In addition,
utilization of our chemical shift assignments of NaV1.5 DIV S3-S4 paddle motif will allow
for the rapid elucidation of structural interactions initiated by various site 3 toxins
(including novel toxins) that target NaV1.5 (provided that the signal does not disappear).
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Chapter 5
Concluding Remarks and Future Directions

Peptide neurotoxins are believed to hold the secret to treating many
channelopathies owing to their high affinity (dissociation constant typically in the nM
range) and NaV isoform selectivity. Here we have presented the ground work to
extracting and possibly exploiting interactions governing the strong and specific binding
between peptide neurotoxins and their cognate receptors. Firstly we solved the first 3D
structure of a teretoxin, Tv1 (79). Tv1 has been shown to possess biological activity
when tested on polychaete worms although its molecular target remains to be
determined. One possible way to determine its cognate receptor is to immobilize Tv1 on
a resin and treat this resin with polychaete lysate in an effort to pull down, enrich, and
possibly identify the target through mass spectrometry sequencing. Although its cognate
receptor remains elusive, once discovered and purified, various molecular biological,
specifically site-directed mutagenesis, and biophysical methods such as NMR
spectroscopy (titration and cross saturation), mass spectrometry, and drug design/
modeling experiments can be carried out to determine the modes of interaction. Binding
assays such as SPR and ITC can be used to determine binding affinities. Also once the
molecular target of Tv1 is known peptide engineering can ensue much as was done
with ProToxin II by Park et al (116). ProToxin-II was mutated at various locations within
the peptide with and without truncation, modification, or addition to the C-terminal tail to
increase toxin affinity to both NaV1.7 and NaV1.2 (116). Engineering of known peptide
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neurotoxins can increase affinity, and increase isoform specificity, thereby decreasing
the amount of toxin necessary (lowering the cost to manufacture) and lessening the
side-effects.
Secondly, VSDs are responsible for the three functional states (open, closed, and
inactivated) of VGICs, and to date there has been no structural characterization of a
eukaryotic VSD. Even though there has been structural characterization from VSDs of
KVs (in isolation and full channels) (28-31) and bacterial NaVs (full channels) (32, 33,
34), these VSDs are identical in each of the four domains of their respective
homotetrameric channels, where as in eukaryotic NaVs the channel is formed by
pseudotetrameric domains which contain differences in sequence and therefore behave
kinetically different. Here we have demonstrated the bacterial expression of an isolated
VSD of a eukaryotic NaV, specifically VSD IV of the human cardiac sodium channel
NaV1.5. We have isotopically labeled this VSD, used it to pull down spider peptide
neurotoxins, and placed the VSD in isotropic bicelles. The work of chapter 3 lays the
foundation for performing 3D heteronuclear experiments and making backbone
assignments of a NaV VSD. Although our studies of VSD IV of NaV1.5 show
conformational heterogeneity, locking the VSD into one conformation with the aid of a
site 3 neurotoxin may reduce the conformational heterogeneity, improving spectral
quality leading to the possibility of recording high quality spectral data. Our lab has
synthesized the sea anemone toxin ApA with some success, therefore this hypothesis
can be tested in the future with 15N-TROSY titration experiments. If titration experiments
of NaV1.5 VSD IV with ApA prove successful we can test the feasibility of 3D NMR
backbone experiments (HNCO, HNCA, HNCOCA…) in a similar way to what we have
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done with NaV1.5 DIV S3-S4 paddle motif. This would provide the first backbone
assignments of a mammalian NaV VSD.
Paddle motifs are the recognition site of the gating-modifier toxins (8), and
although this is the recognition site of two important classes of toxins (site 3 and 4
toxins), the interaction between the two is not well characterized on the atomistic level.
To address this lack of information, we have synthesized and expressed the paddle
motif from VSD IV of NaV1.5. We expected that the paddle motif of NaV1.5 DIV would
take a similar fold to the already solved structure of the paddle motif from the HsapBK
K+ channel in n-DPC micelles (115). CD analysis of a NaV1.5 DIV S3-S4 paddle motif
suggests that it has α-helical character as seen from the structure of the HsapBK K+
channel paddle motif. We have run all of the necessary 2D and 3D heteronuclear
experiments to obtain backbone assignments for the paddle motif peptide. With these
as a foundation we can begin experiments such as

15N-edited

NOESY-HSQC to derive

the 3D fold to produce the first recorded three dimensional structure of a mammalian
NaV paddle motif. Running of sophisticated titration and cross saturation NMR
experiments will begin to unravel, with atomic precision, the residues and key
interactions involved in peptide neurotoxin/NaV paddle motif interaction, recognition, and
binding. Such studies have been initiated with our studies on the interaction of ApA and
NaV1.5 DIV S3-S4 paddle motif. Taken as a whole, the work presented in this
dissertation provides several avenues for continued investigation that should result into
novel insights into peptide neurotoxins and mammalian Na ion channel biology and
biochemistry.

80

Service Description
Optimization (for Escherichia coli) and synthesis of Gene1, with sequence verification and
standard cloning into pUC57-Amp; delivered as a mini-scale DNA preparation.
Note: pUC57 contains several common restriction sites. While standard cloning into pUC57 typically is via
EcoRV, the exact restriction site(s) used for each sequence may vary. GENEWIZ may maintain or exclude
specific restriction sites within the MCS upon request. Please contact GENEWIZ Project Management with
any questions.

Appendix

A1
Sequence of NaV1.5VSDIV
Sequence Analysis
NcoI, XhoI, KpnI, NdeI, BamHI, EcoRI excluded during optimization
The protein sequence of Gene1
RPLNKYQGFIFDIVTKQAFDVTIMFLICLNMVTMMVETDDQSPEKINILAKINLLFVAIFTGECIVKLAALRHYYFTNS
WNIFDFVVVILSIVGTVLSDIIQKYFFSPTLFRVIRLARIGRILRLIRGAKGIRTLLFALMMSLPALFNI

The optimized (for Escherichia coli) sequence of Gene1
A 91 T 101 C 144 G 111 | GC%: 57.05% | Length: 447
CGTCCGCTGAACAAGTACCAGGGCTTCATCTTCGACATCGTGACCAAGCAGGCCTTCGACGTGACCATCATGTTCCTGA
TCTGCCTGAACATGGTGACCATGATGGTTGAGACCGACGACCAGAGCCCGGAGAAGATCAACATCCTGGCCAAGATCAA
CCTGCTGTTCGTGGCCATCTTCACCGGTGAGTGCATCGTGAAGCTGGCCGCCCTGCGCCACTACTACTTCACCAACAGC
TGGAACATCTTCGACTTCGTGGTTGTGATCCTGAGCATCGTGGGCACCGTGCTGAGCGACATCATCCAGAAGTACTTCT
TCAGCCCGACCCTGTTCCGCGTTATCCGCTTAGCCCGCATCGGCCGTATCCTGCGCTTAATCCGCGGTGCCAAGGGCAT
CCGCACACTGCTGTTCGCACTGATGATGAGCCTGCCGGCCCTGTTCAACATC

2
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A2 SDS-PAGE Analysis
Samples were prepared in 1:2 volume ratio of sample:sample buffer.
Samples were then sonicated in a low powered bath sonicator for 5 minutes.
Samples were then heated for 3-5minutes at 95℃ (membrane protein samples were
not boiled).
Samples were then loaded on to either Any kD™ Mini-PROTEAN® TGX™ Precast
Protein Gels (Bio-Rad) or home poured 15% poly-acrylamide gels.
Gels were run at 120 V until protein marker reached resolving gel and began separation
at which voltage was increased to 180 V.
Gels were then stained either stained with Pierce™ Silver Stain Kit (Thermo Fisher
Scientific Inc.) or 0.1% Coomassie Brilliant Blue in 40% methanol, 10% acetic acid.

All Recipes can be found in the Mini-PROTEAN® Tetra Cell Instruction Manual (BioRad)
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A3 Western Blot Analysis
Protein gels were incubated in transfer buffer for 15 minutes, as was nitrocellulose
membrane and blotting paper (protein gels separate from nitrocellulose membranes and
blotting paper).
Transfer of protein from protein gels to nitrocellulose paper was carried out using a BioRad Trans-Blot® SD Semi-Dry Transfer Cell at 15 V for 20 minutes.
Nitrocellulose membranes were then treated with blocking buffer (TBST+ 0.1% BSA) for
1 hour at room temperature or 4℃ overnight.
Nitrocellulose membranes were then treated with 1° mouse anti-6XHis antibody for 1
hour at room temperature in blocking buffer. (1:3000 dilution)
Nitrocellulose membranes are then washed 1X for 15 minutes with TBST and 3X for 5
minutes with TBST
Nitrocellulose membranes are then treated with 2° goat anti-mouse HRP antibody in
blocking buffer for 1 hour at room temperature. (1:3000 dilution)
Nitrocellulose membranes are then washed 1X for 15 minutes with TBST and 3X for 5
minutes with TBST.
Nitrocellulose was then treated with SuperSignal™ West Pico Chemiluminescent
Substrate (Thermo Fisher Scientific Inc.) following the manufacturers protocol and
imaged.
Transfer Buffer: 25 mM Tris, 192 mM glycine, 0.3 % SDS, 25 % methanol
10X TBS: 200 mM TRIS (pH7.4), 1.5 M NaCl
TBST: 1X TBS + 0.05% Tween-20
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A4 M63 Growth Medium
M63 Buffer:
For 1 L of growth medium:
Add 13.6 g KH2PO4, 4 g KOH, 100 μL FeSO4 stock (500 mg FeSO4*7H2O + 100 ml 0.01N HCl) and 0.5
-1.0 g 14/15NH4Cl to 900 mL H2O, check pH and adjust if necessary, autoclave.
Autoclave 6 g (2-14 g) glucose in 100 mL H2O separately.
Before inoculation, combine M63 medium and glucose and add:
1 mL vitamin mix
1 mL Mg solution
5 mL solution C
Antibiotic
Supplements
Mg solution:

1M stock. 24.6 gm MgSO4*7H2O / 100 ml.
Autoclave separately.

Vitamin mix (for 50 mL, filter-sterilize and store at 4 °C, wrapped in foil):
nicotinic acid
100 mg
thiamin * HCl
50 mg
para-aminobenzoic acid 10 mg
biotin
1 mg
Solution C stock:

(mineral solution for growth in minimal media, filter sterilize and store at 4 °C)
Per Liter:
Nitrilotriacetic acid (wear gloves)10.0 g
MgCl2 * 6H2O
24.0 g
CaCl2 * 2H2O
3.335 g
Metals 44 (see below)
50 mL
KOH
7.3 gm
Dissolve KOH in ~ 500 mL of ddH2O. Add NTA, dissolve, then add the remaining ingredients and adjust to
pH 6.7-6.8 with 5M and 1M KOH (~8.5 mL of 5M KOH). Allow any precipitate to dissolve between
additions of KOH. As the precipitate dissolves, the pH changes (takes a while to adjust pH).
Metals 44:

(without sulfur, sodium, or potassium; high in iron and molybdenum)
grams per Liter:
EDTA
2.5
ZnCl2
5.22
FeCl2 * 4H2O
5.02
MnCl2 * 4H2O
1.8
(NH4)6Mo7O24 * 4H2O
0.185
CuCl2 * 2H2O
0.156
Co(NO3)2 * 6H2O
0.248
Boric acid
0.144

Mix chemicals in ~500 mL ddH2O. After dissolved, bring volume to 1.0 L. pH will be ~ 4. The
solution will appear green, and will oxidize over time and turn yellowish.
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